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ABSTRACT OF DISSERTATION

NONLINEAR HIERARCHICAL MODELS FOR LONGITUDINAL EXPERIMENTAL
INFECTION STUDIES
Experimental infection (EI) studies, involving the intentional inoculation of
animal or human subjects with an infectious agent under controlled conditions, have a
long history in infectious disease research. Longitudinal infection response data often
arise in EI studies designed to demonstrate vaccine efficacy, explore disease etiology,
pathogenesis and transmission, or understand the host immune response to infection.
Viral loads, antibody titers, symptom scores and body temperature are a few of the
outcome variables commonly studied. Longitudinal EI data are inherently nonlinear,
often with single-peaked response trajectories with a common pre- and post-infection
baseline. Such data are frequently analyzed with statistical methods that are inefficient
and arguably inappropriate, such as repeated measures analysis of variance (RMANOVA). Newer statistical approaches may offer substantial gains in accuracy and
precision of parameter estimation and power. We propose an alternative approach to
modeling single-peaked, longitudinal EI data that incorporates recent developments in
nonlinear hierarchical models and Bayesian statistics. We begin by introducing a
nonlinear mixed model (NLMM) for a symmetric infection response variable. We
employ a standard NLMM assuming normally distributed errors and a Gaussian mean
response function. The parameters of the model correspond directly to biologically
meaningful properties of the infection response, including baseline, peak intensity, time
to peak and spread. Through Monte Carlo simulation studies we demonstrate that the
model outperforms RM-ANOVA on most measures of parameter estimation and power.
Next we generalize the symmetric NLMM to allow modeling of variables with
asymmetric time course. We implement the asymmetric model as a Bayesian nonlinear
hierarchical model (NLHM) and discuss advantages of the Bayesian approach. Two
illustrative applications are provided. Finally we consider modeling of viral load. For
several reasons, a normal-errors model is not appropriate for viral load. We propose and
illustrate a Bayesian NLHM with the individual responses at each time point modeled as
a Poisson random variable with the means across time points related through a Tricube
mean response function. We conclude with discussion of limitations and open questions,
and a brief survey of broader applications of these models.

KEYWORDS: Bayesian nonlinear hierarchical model, infection response, viral
challenge, simulation study, longitudinal data analysis

Michael Singleton
April 30, 2015

NONLINEAR HIERARCHICAL MODELS FOR LONGITUDINAL
EXPERIMENTAL INFECTION STUDIES

By
Michael David Singleton

Patrick Breheny
Co-Director of Dissertation
Wayne Sanderson
Co-Director of Dissertation
Steve Browning
Director of Graduate Studies
April 30, 2015

To Zhenyu, Evan and Emma

ACKNOWLEDGEMENTS
There are several individuals without whose contributions I could not have seen
this work to completion. First and foremost I thank my wife, Zhenyu, and my children,
Evan and Emma, for their patience during these past two years. I love you!
I thank my committee chair, Patrick Breheny, for his steadfast support and
encouragement throughout the process. To my other committee members from the
Departments of Epidemiology and Biostatistics – Wayne Sanderson, Steve Browning and
Richard Charnigo – thanks for feedback which greatly improved the final product.
Special thanks to committee member Udeni Balasuriya – whose experimental
infection studies on equine arteritis virus at the University of Kentucky’s Gluck Equine
Research Center were the inspiration for this dissertation – and to his students Yun
Young Go and Juliana Campos, who generously provided data from their studies. Thanks
also to Patrick Mallia and Jennifer Owen for permission to use data from their
experimental infection studies.

iii

TABLE OF CONTENTS
Acknowledgements ....................................................................................................... iii
List of Tables.................................................................................................................vii
List of Figures ................................................................................................................ ix
Chapter One - Literature review ....................................................................................... 1
1.1

Introduction .............................................................................................. 1

1.2

A brief overview of the uses of experimental infection studies .................. 4

1.3

Experimental infection case studies .......................................................... 7
1.3.1 The role of host genetic factors in the pathogenesis of Equine Viral
Arteritis ........................................................................................ 7
1.3.1.1 “Assessment of correlation between in vitro CD3+ T cell
susceptibility to EAV infection and clinical outcome
following experimental infection” ..................................... 8
1.3.1.2 “Semen quality of stallions challenged with the Kentucky
84 strain of equine arteritis virus” .................................... 10
1.3.2 Effects of rhinovirus infection in chronic obstructive pulmonary
disease ........................................................................................ 10
1.3.3 Effect of body condition on viral shedding in migratory birds ..... 13

1.4

Longitudinal EI data ............................................................................... 16
1.4.1 Nature of longitudinal EI data ..................................................... 16
1.4.2 Traditional approaches to the analysis of longitudinal EI data ..... 17
1.4.3 Alternative approaches to data analysis ....................................... 17

1.5

Nonlinear hierarchical models for longitudinal EI data ........................... 19
1.5.1 Background................................................................................. 19
1.5.2 The normal-errors NLHM ........................................................... 21
1.5.3 Application to EI studies ............................................................. 23

1.6

Scope and outline of dissertation ............................................................ 25

1.7

Ethical considerations in EI studies ......................................................... 27

iv

Chapter Two: A nonlinear mixed model for a single-peaked, symmetric response ......... 30
2.1

Introduction ............................................................................................ 30

2.2

Normal-errors model for a symmetric response....................................... 30
2.2.1 Implementation as a nonlinear mixed model ............................... 32

2.3

Simulation .............................................................................................. 32
2.3.1 Data-generating models .............................................................. 33
2.3.2 One-sample simulation: method .................................................. 34
2.3.3 One-sample simulation: results ................................................... 36
2.3.4 Two-sample simulation: method ................................................. 44
2.3.5 Two-sample simulation: results ................................................... 45

2.4

Illustrative example ................................................................................ 50

2.5

Discussion .............................................................................................. 53
2.5.1 Simulation: estimation ................................................................ 54
2.5.2 Simulation: type I error control and power .................................. 55
2.5.3 Illustrative example ..................................................................... 56

Chapter Three: A Bayesian hierarchical model for a single-peaked, asymmetric response
3.1

Introduction ........................................................................................... 57

3.2

Normal-errors NHLM for an asymmetric response ................................. 58
3.2.1 Modeling an asymmetric infection response ................................ 58
3.2.2 Statement of the model................................................................ 59
3.2.3 Bayesian implementation ............................................................ 60

3.3

Illustrative examples ............................................................................... 62
3.3.1 Lymphocyte response to equine arteritis virus infection in
Horses......................................................................................... 62
3.3.2 Febrile response to equine arteritis virus infection in horses ........ 66

3.4

Estimation and inference for onset and recovery times in the
normal-errors NLHM ............................................................................. 70
3.4.1 Method ....................................................................................... 70
3.4.2 Procedure .................................................................................... 72
3.4.3 Illustrative example: Lymphocyte count ...................................... 73
3.4.4 Illustrative example: Febrile response ......................................... 73
v

3.5

Discussion .............................................................................................. 75
3.5.1 Illustrative examples ................................................................... 76
3.5.2 Estimation and inference for response onset and recovery ........... 78

Chapter Four: A Bayesian nonlinear hierarchical model for viral load ........................... 79
4.1

Introduction ............................................................................................ 79

4.2

Bayesian nonlinear hierarchical model for viral load............................... 80

4.3

Illustrative examples ............................................................................... 81
4.3.1 Effect of body condition on viral shedding in migratory birds ..... 81
4.3.2 Effects of rhinovirus infection in chronic obstructive pulmonary
disease ........................................................................................ 84

4.4

Onset and recovery times in the viral load NLHM .................................. 88

4.5

Discussion .............................................................................................. 90
4.5.1 Illustrative examples ................................................................... 92

Chapter Five: Summary and future directions…………………………………………...95
5.1

Nonlinear hierarchical models for longitudinal EI studies ....................... 95

5.2

Limitations and open questions ............................................................... 97

5.3

Broader applicability .............................................................................. 98

Appendix A ................................................................................................................. 100
References ................................................................................................................... 121
Vita ............................................................................................................................. 136

vi

LIST OF TABLES

Table 2.1

Effect of number of subjects on parameter estimation in normal-errors
NLMM and one-way RM-ANOVA ........................................................ 40

Table 2.2

Effect of sampling intensity on parameter estimation in NLMM and oneway RM-ANOVA .................................................................................. 41

Table 2.3

Effect of variability in time to peak response on parameter estimation in
one-sample NLMM and one-way RM-ANOVA ..................................... 42

Table 2.4

Comparison of NLMM and RM-ANOVA when NLMM response function
is incorrectly specified ............................................................................ 43

Table 2.5

Type I error rate by sample size for NLMM and RM-ANOVA ............... 46

Table 2.6

Effect of number of subjects on power to detect a true difference in
response to infection in two-sample NLMM and two-way
RM-ANOVA .......................................................................................... 48

Table 2.7

Effect of number of subjects on power to detect a true difference in
response to infection in two-sample NLHM and two-way RM-ANOVA –
NLMM mean response function incorrectly specified ............................. 49

Table 2.8

Estimates of population febrile response parameters following challenge
of eight mares with Bucyrus strain of EAV and eight stallions KY-84
strain of EAV ......................................................................................... 51

Table 3.1

Posterior estimates of population lymphocyte response parameters
following challenge of eight mares with the virulent, recombinant Bucyrus
strain of EAV ......................................................................................... 65

Table 3.2

Posterior estimates of population febrile response parameters following
challenge of eight mares with the Bucyrus strain of EAV and eight
stallions with the KY-84 strain of EAV .................................................. 68

Table 3.3

Posterior estimates of group differences in population infection response
parameters .............................................................................................. 69
vii

Table 4.1

Posterior estimates of population viral shedding parameters for captive
normal and wild lean groups experimentally challenged with AIV .......... 83

Table 4.2

Posterior estimates of differences in population viral shedding parameters
for wild normal and wild lean groups experimental challenged with AIV84

Table 4.3

Posterior estimates of population viral load response parameters for
controls and subjects with COPD............................................................ 86

Table 4.4

Posterior estimates of differences in population viral load response
parameters for controls and subjects with COPD .................................... 88

viii

LIST OF FIGURES

Figure 1.1

Google Scholar references containing the phrase “experimental infection”
in the title by decade, 1890-2009 .............................................................. 6

Figure 1.2

Observed core body temperature profiles by phenotype group for eight
mares following experimental challenge with EAV .................................. 9

Figure 1.3

Mean core body temperature by phenotype group ..................................... 9

Figure 1.4

Observed profiles of viral load in nasal lavage for eleven subjects with
COPD and twelve health controls following experimental challenge with
RV-16 .................................................................................................... 12

Figure 1.5

Mean viral load in nasal lavage for COPD and control groups ................ 12

Figure 1.6

Mean shed virus by treatment group ....................................................... 15

Figure 1.7

Observed viral shedding profiles for nine captive bred ducks with normal
body condition and nine wild-caught ducks with lean body condition
following experimental challenge with AIV............................................ 15

Figure 1.8

Gaussian, Tricube and Epanechnikov kernel functions………………….24

Figure 2.1

Population response curves for two-sample simulation………………….47

Figure 2.2

Observed febrile response profiles for eight mares challenged with the
Bucyrus strain of EAV, and eight stallions challenged with the Kentucky84 strain ................................................................................................. 50

Figure 2.3

Population febrile response curves, with pointwise 95% posterior credible
intervals, for mares challenged with the Bucyrus strain of EAV, and
stallions challenged with the Kentucky-84 strain .................................... 52

Figure 3.1

Response shapes accommodated by a piecewise Gaussian function ........ 59

Figure 3.2

Observed lymphocyte response profiles for eight mares challenged with
the virulent, recombinant Bucyrus strain of EAV .................................... 63

ix

Figure 3.3

Square root-transformed lymphocyte response profiles ........................... 63

Figure 3.4

Population lymphocyte response curve, with pointwise 95% posterior
credible intervals, for eight mares following experimental challenge with
the virulent, recombinant Bucyrus strain of EAV .................................... 65

Figure 3.5

Observed febrile response profiles for eight mares challenged with the
Bucyrus strain of EAV, and eight stallions challenged with the Kentucky84 strain ................................................................................................. 66

Figure 3.6

Population febrile response curves, with pointwise 95% posterior credible
intervals, for mares challenged with the Bucyrus strain of EAV, and
stallions challenged with the Kentucky-84 strain .................................... 69

Figure 3.7

Estimated population mean onset and recovery times for lymphocyte
response for mares challenged with the recombinant Bucyrus strain of
EAV ....................................................................................................... 73

Figure 3.8

Estimated population mean onset and recovery times for febrile response
to EAV infection .................................................................................... 74

Figure 4.1

A typical nasal viral load response profile for a human subject
experimentally infected with rhinovirus .................................................. 80

Figure 4.2

Observed viral shedding profiles for nine wild-caught ducks with normal
body condition and nine wild-caught ducks with lean body condition
following experimental challenge with AIV............................................ 82

Figure 4.3

Estimated population viral shedding curves, with pointwise 95% posterior
credible intervals, for wild normal and wild lean groups challenged with
AIV ........................................................................................................ 84

Figure 4.4

Observed profiles of viral load in nasal lavage for eleven subjects with
COPD and twelve health controls following experimental challenge with
RV-16 .................................................................................................... 85

Figure 4.5

Estimated population time course for viral load in nasal lavage, following
RV-16 challenge with pointwise 95% posterior credible intervals ........... 87
x

Figure 4.6

Estimated onset and recovery times, with posterior 95% credible intervals,
for wild normal ducks challenged with AIV............................................ 89

Figure 4.7

Estimated onset and recovery times, with posterior 95% credible intervals,
for wild lean ducks challenged with AIV ................................................ 90

xi

CHAPTER ONE
Literature Review

1.1. INTRODUCTION
In a 1951 article in Scientific American, the eminent Australian virologist Sir
Frank MacFarlane Burnet sounded the death knell for infectious disease, writing:
One can think of the middle of the twentieth century as the end of one of the most
important social revolutions in history, the virtual elimination of infectious
diseases as a significant factor in social life (Burnet 1951).
At the time there was just cause for such optimism. The preceding hundred years had
brought astounding advances in the understanding of the etiology of infectious diseases
and their prevention. Robert Koch and Louis Pasteur, in the latter half of the 19th century,
had established that diseases such as anthrax, rabies, tuberculosis and cholera were
caused by microorganisms and had successfully developed vaccines and medications to
prevent infection (Koch 1884, Koch 1890a, Koch 1890b, Pasteur 1881, Suzor 1887).
Smallpox vaccination programs had eliminated nearly all cases of that disease in the
United States (Chapin 1913). Alexander Fleming had discovered penicillin in 1929 and
subsequent work by Howard Florey, Ernst Chain and Norman Heatley made possible its
mass production. At the same time Burnet wrote the above words, Jonas Salk was on the
verge of commencing human testing of his killed-virus polio vaccine (Meldrum 1998).
However over the next forty years this confidence in the elimination of infectious
disease would be steadily eroded. While many diseases were being successfully
controlled, novel viruses were emerging. Examples include Ebola virus in the 1970’s
(Simpson et al. 1978), the human immunodeficiency virus (HIV) in the early 1980’s
1

(Barre-Sinoussi et al. 1983), and more recently the severe acute respiratory syndrome or
SARS (Fouchier et al. 2003) and the Middle East Respiratory Syndrome Coronavirus
(MERS-CoV). Furthermore, it quickly became apparent that bacteria were far more
resourceful than previously realized. As early as 1942 came the first reports of penicillinresistant strains of Staphylococcus aureus (Rammelkamp and Maxon 1942). Within two
decades as many as 80% of staphyolococcal isolates were resistant to penicillin (Lowy
2003). In light of developments such as these, it has become clear that infectious disease
research, epidemiology and prevention are as relevant and important as ever.
Experimental infection (EI) studies, involving the intentional inoculation of
animal or human subjects with an infectious agent under controlled conditions, have
played a central role in infectious disease research and epidemiology for more than two
hundred years. Most of the early work of Koch and Pasteur cited above involved the
experimental inoculation of small mammals such as rabbits and guinea pigs. Today there
are hundreds of animal challenge models for infectious diseases (Zak and O’Reilly 1993).
But experimental infection studies are not limited to animals. Certain diseases lack
effective animal models, and even when they do exist, human models are often preferred
when they can be safely and ethically employed. Human challenge models are used to
study self-limiting respiratory infections such as rhinovirus, influenza and respiratory
synctitial virus (Ramos et al. 2014, DeVincenzo et al. 2014, Wilkinson 2012), and
models have been developed or proposed for Helicobacter pylori (Michetti 2004), cholera
(Shirley and McArthur 2011), malaria (Sauerwein et al. 2011), gonorrhea (Hobbs et al.
2011), tuberculosis (Hokey 2014) and others.
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In early EI studies the outcome of interest was usually the simple presence or
absence of disease. Eventually investigators became interested in studying the time
course of various aspects of the infection response. A major milestone in the development
of a polio vaccine, for instance, was Dorothy Horstmann’s 1952 time course EI study
which demonstrated the occurrence of viremia in monkeys following oral inoculation
with poliomyelitis virus (Horstmann 1952). The knowledge that the virus reached the
nervous system via the bloodstream led researchers to focus on development of an oral
polio vaccine that would to elicit antibodies in the blood and gastrointestinal tract
(Carleton 2011).
With advances in microbiology and technology, increasingly sophisticated
questions are being investigated using time course EI studies. Yet the statistical
approaches used to model and analyze time course data from EI studies have remained
largely unchanged for at least thirty years, despite major advances in methods for
analyzing longitudinal data that have occurred during that period. The most popular
approaches traditionally have been 1) the analysis of variance for repeated measures
(RM-ANOVA) and 2) multiple horizontal or vertical contrasts (Ludbrook 1994) using ttests or their nonparametric equivalents (Paillot et al. 2013, Munhoz et al. 2012, Cray et
al. 1995, Suter et al. 1985, Higgins et al. 1983). The aim of this dissertation is to propose
an alternative approach to the analysis of longitudinal data from EI studies that draws
upon recent developments in the areas of nonlinear hierarchical models and Bayesian
statistics.
We begin by reviewing the various roles that EI studies have played in the study
of infectious diseases. Next we narrow our focus by describing in detail four time course
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EI studies on which we will draw in subsequent chapters for illustrative examples of our
methods. We review some objections that have been raised to traditional methods of
analyzing data from such experiments. Finally we outline the specific aims of this
dissertation.
1.2. A BRIEF OVERVIEW OF THE USES OF EXPERIMENTAL INFECTION
STUDIES
Long before the causal link between microorganisms and disease had been
decisively proven, physicians and scientists were conducting EI studies. In 1796, in one
of the earliest tests of vaccine efficacy, England physician Edward Jenner challenged an
eight year-old boy with live smallpox two months after inoculating him with cowpox
vaccine (Riedel 2005; Willis 1997). As part of his work on a rabies vaccine in the latter
part of the nineteenth century in France, Pasteur performed EI studies on rabbits (Franco
2013). In the mid-twentieth century polio research and vaccine development relied
heavily on the experimental infection of monkeys (Oshinsky 2006). Several candidate
cholera vaccines have been tested in human challenge trials (Shirley and McArthur 2011,
Herrington et al. 1990 Tacket et al. 1990). Recently, controlled human malaria infection
has been used as a method of evaluating candidate malaria vaccines (Laurens et al. 2012,
Roestenberg et al. 2013, Targett et al. 2013). Human challenge models for self-limiting
respiratory infections such as influenza, human rhinovirus and respiratory synctitial virus
are being used to accelerate proof of concept for vaccines against respiratory viruses
(Ramos et al. 2014, DeVincenzo et al. 2014).
Many early EI studies were concerned with establishing the infectious etiology of
a known disease. In a historic lecture in 1882, Koch demonstrated the infectious etiology
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of tuberculosis and identified the causative agent, Mycobacterium tuberculosis. His
discovery was accomplished by experimentally infecting guinea pigs with material from
tuberculosis-infected human and animal sources (Koch et al. 1982). Similarly, his work
on the etiology of anthrax involved the experimental infection of mice with Bacillus
anthracis (Koch 1876). Koch would subsequently publish his postulates for causation in
1890. Since that time, EI studies have been used to demonstrate the etiological agents for
many infectious disease. More recently an etiologic link between Helicobacter pylori, a
gastrointestinal bacterium which was discovered in 1982 (Marshall and Warren 1984),
and type B gastritis has been established largely through EI studies in both human
volunteers and animal models (Blaser 1990).
Another historically important use of experimental infection has been to establish
the route by which an infectious agent is transmitted to the host. Carlos Finlay in 1881
proposed that the Culex mosquito was the agent responsible for the transmission of
yellow fever mosquito (Finlay 1881). To test his hypothesis he conducted a series of 102
experimental infections of human volunteers, the results of which were generally viewed
as inconclusive (Sternberg1891, Sternberg 1901). His experiments were subsequently
repeated, and his theory confirmed, in further human volunteer experiments led by Walter
Reed (Reed et al. 1900). Contemporary with Finlay and Reed, Ronald Ross 1897
conducted EI studies in birds to demonstrate transmission of malaria parasites by
mosquito (Bynum 1999). Killingley et al (2011) recently reviewed the potential
contributions of human challenge studies to research on mechanisms of influenza
transmission.

5

EI studies have played a central role in experimental immunology, where they
have helped to advance basic understanding of the immune response to infection.
Representative examples include Wilkinson et al. 2012; Henriques et al. 2012; Gaunt et
al. 2010; McMichael et al. 1981. Numerous journals, including Viral Immunology,
Vaccine, Journal of Immunology and others, are dedicated to clinical, translational and
basic research into the immune response to viral infections.

Number of references

3000
2500
2000
1500
1000
500
0

Figure 1.1. Google Scholar references containing the phrase
“experimental infection” in the title by decade, 1890-2009
Scholarly papers containing the phrase “experimental infection” can be found
from as early as 1899. Figure 1.1 shows the number of references by decade retrieved by
Google Scholar (2013) containing the phrase “experimental infection” in the title. The
number of published studies rose gradually through the mid-1940’s and then increased
dramatically over the next four decades. This data indicates that hundreds of EI studies
are currently being published annually in peer-reviewed journals around the world. The
applications discussed in this section – vaccine efficacy, etiology, transmission and basic
immunology – represent only some of the most common applications.
6

1.3. EXPERIMENTAL INFECTION CASE STUDIES
The focus of this dissertation is EI studies in which the response variable is
measured repeatedly on one or more groups of subjects over time. We will refer to such
experiments as repeated measures, time course, or longitudinal EI studies. In this section
we give detailed descriptions of four recent longitudinal EI studies. These case studies
will provide context for the discussion of our research aims as well as background for the
illustrative examples in subsequent chapters. We consider these examples to be a
representative cross-section of mainstream approaches to analyzing time course data from
EI studies. Later chapters will explore alternative methods.
1.3.1. The role of host genetic factors in the pathogenesis of Equine Viral Arteritis
Equine arteritis virus (EAV) is the causative agent of a respiratory and
reproductive disease of equids known as equine viral arteritis (EVA). The virus was first
isolated in 1953 on a Standardbred breeding farm in Bucyrus, Ohio during an outbreak of
respiratory illness and abortion (Doll et al. 1957). Numerous other outbreaks have
occurred throughout the world since that time, including an epizootic among
thoroughbreds in Kentucky in 1984 (Timoney et al. 1986). EAV is a major concern to
horse breeders because it can cause spontaneous abortion in mares and temporary
subfertility in stallions. Furthermore, 30% to 70% of exposed stallions will become longterm carriers of the virus, continuing to shed virus in semen after all clinical signs of
infection have ceased (Timoney et al. 1986). Such carrier stallions constitute the natural
reservoir for EAV, and venereal transmission from a carrier stallion, either directly or via
artificial insemination, is the source of many outbreaks. The virus is also transmitted via
the respiratory route (Holyoak et al. 2008).
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It has been observed in natural outbreaks that the severity and clinical signs of
EVA show considerable variation, both among individual horses in the same outbreak
and between different outbreaks. Numerous factors may influence the course of infection
including the age and physical condition of the horse, the viral strain and the received
dose (Balasuriya et al. 2007, Holyoak et al. 2008). Recently it has been proposed that
host genetic factors may also play a role in EAV pathogenesis. Balasuriya and colleagues
have identified a haplotype that is associated with susceptibility of CD3+ T lymphocytes
to infection by a recombinant virulent Bucyrus strain (VBS) of EAV. They classified
horses as possessing the “resistant” or “susceptible” phenotype based on the ability of the
VBS to infect in vitro their CD3+ T lymphocytes (Go et al. 2010). Recently, they
conducted two related experiments to assess whether the response to EAV infection
differs between horses with the resistant and susceptible phenotypes.
1.3.1.1. “Assessment of correlation between in vitro CD3+ T cell susceptibility to
EAV infection and clinical outcome following experimental infection”
In the first experiment, by Go et al. (2011), four mares possessing the in vitro
susceptible CD3+ T cell phenotype were identified along with four possessing the
resistant phenotype. All eight mares were inoculated with the recombinant, virulent
Bucyrus strain of EAV. Clinical signs, viral load, complete blood cell counts and serum
neutralizing antibodies were monitored over a period of seven weeks, which included a
seven-day baseline observation period. We focus here on comparison of the mean febrile
response in the two groups as measured by core body temperature (CBT), which was
observed on the morning of days -7, -4 and -2 prior to inoculation and on both morning
and evening of days 0, 2, 4, 6, 8, 10, 12 and 14 post-inoculation (DPI). Figure 1.2
presents the observed febrile responses for all four mares in each group.
8

Figure 1.2. Observed core body temperature profiles by phenotype group for eight mares
following experimental challenge with EAV (Go et al. 2011)

Figure 1.3. Mean core body temperature by phenotype group. Significant differences
(𝑝 < 0.05) were reported on days 7 and 9 based on RM-ANOVA with post-hoc testing
for group differences by Holm-Sidak method1.

1

Reprinted from Veterinary Microbiology 2012;157(1-2), Go et al, Assessment of correlation between in

vitro CD3+ T cell susceptibility to EAV infection and clinical outcome following experimental infection,
pages 220-225, Copyright 2012, with permission from Elsevier.
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A global test of the hypothesis of no group difference in febrile response was
conducted using two-way repeated measures analysis of variance (RM-ANOVA). The
Holm-Sidak method (Holm 1979) was subsequently used to identify specific time points
at which CBT differed significantly between phenotype groups. Significant differences
(𝑝 < 0.05) were reported on days 7 and 9 (Figure 1.3). These findings were taken as
evidence of an association between CD3+ T lymphocyte phenotype and febrile response.
1.3.1.2. “Semen quality of stallions challenged with the Kentucky 84 strain of equine
arteritis virus”
The findings of a follow-up to the Go experiment with similar design, but using
stallions instead of mares and a different strain of EAV, were published by Campos et al.
in 2014. One of the primary aims of that experiment (the results of which have not been
published to date) was to assess whether the CD3+ T cell phenotype may play a role in
development of the long-term EAV carrier state in the stallion. Although not the primary
focus of that particular paper, febrile response and other clinical signs were also recorded
as was done in Go et al. (2011).
In Chapters 2 and 3 we re-analyze the EAV febrile response data from the two
experiments by Go and Campos.
1.3.2. Effects of rhinovirus infection in chronic obstructive pulmonary disease
The first human rhinoviruses (HRV) were discovered in the 1950’s. Since that
time 99 serotypes have been identified. HRV is the most common cause of upper
respiratory infection worldwide. In recent years, rhinovirus infection has also been
implicated as an important factor in exacerbations of asthma and chronic obstructive
pulmonary disease (COPD) (Henderson 2013).
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To overcome the difficulties involved in studying the role of respiratory infections
in naturally occurring exacerbations, researchers have developed human challenge
models. Studies employing HRV challenge models in asthma include those by Message
et al. (2008); Contoli et al. (2006); Wark et al. (2005), Grunberg et al. (2001) and Bardin
et al. (2000).
Similarly, Mallia and colleagues (2006, 2011, 2012, 2013) have developed an
HRV challenge model for COPD. For their 2011 study, thirteen volunteers with COPD
and thirteen controls with a similar smoking history, but normal lung function, were
recruited. All participants tested negative for serum neutralizing antibodies to rhinovirus
16 (RV-16). All twenty-six subjects were inoculated with a 10 TCID50 dose of RV-16
and followed for six weeks post-infection. Viral loads in nasal lavage and sputum, lung
function, inflammatory markers, and upper and lower respiratory symptom scores were
sampled at varying intervals and intensities. Twenty-three subjects displayed virological
evidence of rhinovirus infection: eleven from the COPD group and twelve from the
control group. Data from those 23 subjects were analyzed to assess whether experimental
RV-16 infection induces exacerbation in persons with COPD.
Figure 1.4 presents the observed, individual profiles of viral load in nasal lavage
(VLN) following inoculation over the course of six weeks. For most subjects, VLN
increased to a peak very rapidly returned to baseline (zero) more gradually, as the host
immune response neutralized and eliminated the virus. The figure suggests that the mean
time to complete viral clearance may be greater in the control group – although this
impression is based largely on just two control subjects with clearance times greater than
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thirty days – and that the peak viral load may be slightly higher in the COPD group.
Figure 1.5 displays the group means at each measurement occasion.

Figure 1.4. Observed profiles of viral load in nasal lavage for eleven subjects with COPD
and twelve health controls following experimental challenge with RV-16

Figure 1.5. Mean viral load in nasal lavage for COPD and control groups
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In the original experiment, tests for differences in the population mean response at
each time point were analyzed using unpaired t tests or nonparametric Mann-Whitney
tests. No adjustment for multiple comparisons was mentioned. Despite higher observed
mean VLN in the COPD group on days 3 through 12, the authors reported a significant
difference (P < 0.05) in population mean viral load on day 6 only. Thus there is some
uncertainty about the interpretation of these findings. Group differences in age, gender
and smoking status further complicate interpretation. We revisit the HRV viral load data
in Chapter 4.
1.3.3. Effect of body condition on viral shedding in migratory birds
Mallard ducks (Anas platyrhynchos) are an important reservoir for influenza A
virus (IAV), and their migration is a key factor in its global transmission (Webster et al.
1992). The physical strain of migration can cause declines in the birds’ body condition
which may impair immune function (Latorre-Margalef et al. 2009a, Flint and Franson
2009, Latorre-Margalef et al. 2009b). Arsnoe and colleagues conducted an MC
experiment to test the hypotheses that reduced body condition is associated with
increased susceptibility to infection with IAV and with increased peak viral load and
duration of infection (Arsnoe et al. 2011). Thirty seronegative wild-caught mallards were
randomly assigned to three treatment groups. By controlling food availability over a
period of several weeks, differing levels of body condition were established in each
group. Birds in the “normal” treatment group were maintained at ±5% of their baseline
body mass; birds in the “lean” treatment group at −10% of baseline body mass; and birds
in the “poor” treatment group at −20% of baseline body mass. A fourth treatment group
consisted of ten captive-bred mallards given the normal treatment described above. Thus
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four treatment groups were established: wild normal, wild lean, wild poor and captivebred.
When target condition levels were reached, all birds were inoculated with 1.5 mL
of 106 PFU/mL low pathogenic AIV [strain A/Northern pintail/California/44221761/2006 (H5N9)]. Body conditions were maintained over the course of the experiment.
Viral shedding in pooled cloacal and oral swabs was measured by PCR and expressed in
units of 𝑙𝑜𝑔10 (genome equivalent copy numbers), or 𝑙𝑜𝑔10 (𝐺𝐸𝐶 ) , per 140 𝜇𝑙 of swab
fluid. Samples were collected on the first three days post-inoculation and every two days
thereafter until 28 DPI. Mean shed virus by treatment group is presented in Figure 1.7. In
general, groups with higher condition levels (i.e. greater food availability) shed more
virus.
In original analysis, RM-ANOVA was used to compare virus excretion over the
first five DPI. Significant variation among groups was detected (𝐹2,25 , 𝑝 = 0.013). Posthoc group comparisons were carried out using Tukey’s Honestly Signficant Difference
procedure. The only reported difference was that birds in the wild poor treatment group
shed less virus than birds in the wild normal treatment group (M=2.3, p=0.010).
Figure 1.7 presents the individual viral shedding profiles for the captive-bred
control group and the wild lean treatment group. There is considerable inter-individual
variability in shedding patterns, with one of the wild lean birds shedding high levels of
virus and several of the control birds showing low levels. In Chapter 4 we analyze the
viral shedding data in Figure 1.7.
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Figure 1.6. Mean shed virus by treatment group

Figure 1.7. Observed viral shedding profiles for nine captive bred ducks with normal
body condition and nine wild-caught ducks with lean body condition following
experimental challenge with AIV (observations for days 11 through 28 not shown)
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1.4. LONGITUDINAL EI DATA
1.4.1. Nature of longitudinal EI data
Unlike many types of longitudinal data, experimental infection data are inherently
nonlinear, as exemplified by Figures 1.2 through 1.7. We restrict attention in this
dissertation to experiments in which there is exactly one challenge point. In such
experiments, for quantities such as body temperature or viral load there is typically a
brief post-challenge incubation period followed by an interval of rapid increase (the
“onset” phase of the response). As the host’s immune system responds to the infection,
the increase slows and eventually peaks. This is followed by a return to the pre-challenge
baseline level (the “recovery” phase). In the case of viral load typically the level returns
to zero, whereas body temperature will return to the host’s normal baseline level, which
will vary slightly from one individual to the next. This pattern has been referred to as a
single-peaked response to distinguish it from growth curve data (Matthews et al. 1990).
Peaked responses may take other forms, but the present paper focuses on single-peaked
responses with a common pre- and post-challenge baseline level.
Another way in which data arising from EI experiments differs from traditional
longitudinal data is in the frequency with which responses are sampled. Clinical signs
such as core body temperature or symptom scores are routinely observed on twenty or
more occasions over a period of several weeks or months. Furthermore, advances in
biomedical technology have made practical the intensive sampling of viral loads and
various markers of the host immune response (Schochetmann et al. 1988).
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1.4.2. Traditional approach to the analysis of longitudinal EI data
Prior to 1980, repeated measurements data from experimental infection studies
were commonly presented without statistical analysis. By the late 1970’s investigators
were beginning to employ basic statistical methods for comparing group mean responses
(Makinde and Wilkie 1979; Higgins et al. 1983). By the mid-to-late 1990’s formal
statistical analyses had become the norm for EI studies, RM-ANOVA apparently being
the default method (Paillot et al. 2013; Munhoz et al. 2012; Cray and Moon 1995).
However it is unclear whether, among practitioners, much critical thinking has gone into
that decision or whether RM-ANOVA is simply used because it is familiar and
straightforward to use.
Among statisticians the application of RM-ANOVA data to longitudinal data, in
general, has been criticized on several grounds (Matthews et al. 1990, Gueorguieva and
Krystal 2004, Fitzmaurice and Ravichandran 2008). There are concerns about the validity
of certain underlying statistical assumptions. Furthermore, in the case of peaked data, it is
readily apparent that any approach that involves averaging a group of single-peaked
response profiles at each time point will tend to distort the very features of the infection
response that are of greatest interest. Such naïve averaging will tend to produce estimated
population response curves that understate peak intensity and overstate response duration,
as has been described recently by DeVincenzo and colleagues (2010). This effect will
increase as the variability in the time to peak response among subjects increases.
1.4.3. Alternative approaches to data analysis
Numerous alternatives to RM-ANOVA for analyzing longitudinal data exist, most
notably including summary measures or response feature analysis (Matthews et al. 1990),
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multivariate analysis of variance (MANOVA) and the linear mixed model. Each has
strengths and weaknesses which depend on the particulars of the experimental design.
Summary measures may be viable when the individual response profiles can be reduced
to a single, meaningful measure, such as summarizing a linear trajectory by its slope. But
a peaked response curve has numerous features of potential interest which cannot all be
encompassed in a single measure.
MANOVA has the advantage that, unlike RM-ANOVA, it does not impose a
restrictive assumption about the covariance structure of individual response vectors.
Instead, an individual’s responses are treated as a vector arising from a multivariate
normal distribution, the covariance structure of which can be explicitly specified by the
analyst. However MANOVA requires larger numbers of individuals per group to equal
the power of RM-ANOVA, and becomes increasingly unattractive as the number of
observations per individual increases.
The linear mixed model (LMM) retains the ability to specify an appropriate
individual covariance structure. Moreover, if the individual response trajectories are
linear, the performance of the LMM improves as the number of measurement occasions
increases, rather than degrading as with MANOVA. However with a nonlinear response,
time in the LMM must be treated as a factor, which negates this advantage.
Nonparametric regression is an option that is capable of modeling the mean
response curve quite flexibly (Wu and Zhang 2006). Campos et al. (2014) provides an
example of this approach applied to data from an EI study. However the parameters in
nonparametric models (and RM-ANOVA models also) bear no relationship to quantities
of biological interest – such as the timing and intensity of the peak response, and the
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response onset, recovery and duration – which limits inferential options. We propose
another alternative, the nonlinear hierarchical model (NLHM), which among other
features (a) permits direct modeling of the nonlinear mean response trajectories, (b)
allows for meaningful parameterization of the response function, and (c) allows for
flexible modeling of the covariance structure for individual response vectors.
1.5. NONLINEAR HIERARCHICAL MODELS FOR LONGITUDINAL EI DATA
1.5.1. Background
Nonlinear hierarchical models (NLHM) have a history of application in
population pharmacokinetics and pharmacodynamics research (PopPK-PD) dating back
to the early 1970’s (Sheiner et al .1972). Pharmacokinetics is the study of drug
absorption, distribution, metabolism and excretion (Roe 1997). A primary aim of PopPK
modeling is to understand how patient characteristics affect these processes.
Concentration is measured repeatedly over time in a sample of patients following
ingestion of the drug. A NLHM is used to estimate the response of a typical patient as
well as the degree of variation among individual responses and the influence of factors
such as patient age, gender, and body weight on response parameters. Pharmacodynamics
is concerned with the effects of a drug on the patient. The purpose of a PopPD model is
to relate dose or drug concentration to pharmacodynamics effects of the drug (Bonate
2011). In 1980 Sheiner and Beal released NONMEM, a software package for NONlinear
Mixed Effects Modeling which has become the standard for PopPK-PD modeling. An
extensive literature on NLHM’s for PopPK-PD has developed over the past four decades.
Several developments since the early 1990’s have made the NLHM accessible to
a wider audience and increased its range of application. Textbooks on the NLHM were
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published by Davidian and Giltinan in 1995 and Vonesh and Chinchili in 1997. SAS
Version 7, released in 1998, introduced the NLMIXED procedure. In 1999 Pinheiro and
Bates released their package ‘nlme’ (Linear and Nonlinear Mixed Effects Models) in SPlus and subsequently released a version for R, and in 2000 they published an
accompanying textbook. Bayesian implementation of the NLHM has also been facilitated
in recent years by the introduction of software packages for fitting Bayesian models using
Markov Chain Monte Carlo sampling methods, such as BUGS (Bayesian Inference Using
Gibbs Sampling) (MRC Biostatistics Unit 1989), WinBUGS (Lunn et al. 2000), JAGS
(Just Another Gibbs Sampler) (Plummer 2003) and Stan (Stan Development Team 2014).
As a result of these developments, since Sheiner and colleagues’ seminal work on
PopPK-PD the NLHM has been applied to a number of other areas in which nonlinear
repeated measurements arise. Davidian and Giltinan (2003) provided a review of several
of these including dairy science, forestry, toxicokinetics, prostate cancer, circadian
rhythms, cardiology, fisheries science and plant and soil sciences. Of particular relevance
to this dissertation is the application of the NLHM to the dynamics of human
immunodeficiency virus (HIV) (Perelson et al. 1996, Wu et al. 1998, Fitzgerald et al.
2002, Huang 2013). The work on HIV dynamics has led to similar efforts to model
Hepatitis B and C viral dynamics (O’Sullivan et al. 2008, Snoeck et al. 2010). In all three
instances the focus is on the changes in viral load over time that can occur in chronically
infected individuals. We are unaware of any previous efforts to apply the NLHM to the
analysis of data from EI studies involving the intentional challenge of previously
uninfected individuals.
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In the following section we give a brief overview of one form of the NLHM
which Vonesh and Chinchilli (1997) have referred to as the normal-errors NLHM. We
adopt their descriptive term for this model and discuss it in the context of EI studies.
1.5.2. The normal-errors NLHM
Suppose that infection responses for 𝑛 individuals are sampled on multiple
occasions. Let 𝑚𝑖 represent the number of sampling occasions for individual 𝑖 . Let 𝑗
index the sampling times 𝑡1, 𝑡2, ⋯ , 𝑡𝑚𝑖 for individual 𝑖 . Denote the responses for
individual 𝑖 as 𝑦𝑖1, 𝑦𝑖2, ⋯ , 𝑦𝑖𝑚𝑖 , and a vector of covariates for individual 𝑖 at time 𝑗 as 𝒙𝑖𝑗 .
The covariate vectors will include the sampling times, at a minimum, and may also
include measurements on factors other than time – such age, gender or smoking status –
thought to influence an individual’s response to infection. The individual mean infection
response profiles are modeled as a nonlinear function 𝑓 of the covariate vectors 𝒙𝑖𝑗 and a
parameter vector 𝜷𝑖 which is unique to each individual. The model for the individual
infection responses can expressed in terms of the distribution of the response for
individual i at time t.
Level 1 (model of intra-individual variability)
𝑦𝑖𝑗 ~𝑁(𝜇𝑖𝑗 , 𝜎 2 ),

𝜇𝑖𝑗 = 𝑓𝑖 (𝒙𝑖𝑗 , 𝜷𝑖 )

(1.1)

In the normal-errors NLHM, intra-individual deviations from the mean response
trajectory are assumed to follow a multivariate normal distribution. In the form specified
in (1.1), it is further assumed that these errors are independent and identically distributed.
It is possible to relax this assumption and allow for both correlation and heterogeneity in
the intra-individual errors. The interested reader is referred to Davidian and Giltinan
(1995) for details.
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At Level 2 of an NLHM we specify a mechanism by which the individual
response profiles are assumed to be related. This is accomplished by imposing a model
on the response parameters 𝜷𝑖 . A common practice is to assume that they arise from a
multivariate normal distribution with mean 𝜷 and variance-covariance matrix 𝑫. (We
will refer to the components of 𝜷 as the population infection response parameters and the
components of 𝜷𝑖 as the individual infection response parameters.) If all individuals in
the study belong to a single group, then the model of inter-individual variability can be
expressed as follows.
Level 2 (model of inter-individual variability – one group)
𝜷𝑖 = 𝜷 + 𝒃𝑖 ,

𝒃𝑖 ~𝑁(𝟎, 𝑫)

(1.2)

Often in an MC experiment the primary objective is to compare the population
response profiles for two groups – say treatment vs. placebo or presence vs. absence of a
genetic trait thought to influence the response to infection – and interest in the individual
response profiles is secondary. Suppose that the 𝑛 individuals are assigned to two groups
indexed by 𝑔 ∈ {1,2}, and that individual i belongs to group 𝑔. For each group define a
population parameter vector 𝜷(𝑔) which is assumed to give rise to the individual response
vectors for members of group 𝑔. The Level 2 model can then be written as follows.
Level 2 (model of inter-individual variability – two groups)
𝜷𝑖 = 𝜷(𝑔) + 𝒃𝑖 ,

𝒃𝑖 ~𝑁(0, 𝑫(𝑔) )

(1.3)

If we assume that the variance structure is same in both groups then we have
𝜷𝑖 = 𝜷(𝑔) + 𝒃𝑖 ,

𝒃𝑖 ~𝑁(0, 𝑫)

(1.4)

Thus, the normal-errors NLMM provides estimates of the population response
function (or functions) through 𝜷 (or 𝜷(𝑔)), estimates of the individual response functions
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through the 𝜷𝒊 , and estimates of both the intra-individual and inter-individual response
variability through 𝜎 2 and 𝑫 (or 𝑫(𝑔) ). In the two-sample infection response model, the
components of the population response parameters 𝜷(𝑔) can be contrasted to test for
differences in the peak response, time to peak response, and response onset, recovery or
duration between two groups.
The version of the normal-errors NLMM described above permits a great deal of
flexibility in the specification of both the form of the individual infection responses and
the nature of the relationship among them. The model can be extended to make it still
more general. It is possible, for example, to allow for the dependence of the individual
infection response parameters in 𝜷𝑖 on subject characteristics such as age or gender. One
can also specify distributional assumptions on the 𝜷𝑖 other than multivariate normality, or
indeed to avoid distributional assumptions at Level 2 altogether by specifying a
nonparametric or semiparametric model for 𝜷𝑖 . The interested reader is again referred to
Davidian and Giltinan (1995) for details.
1.5.3. Application to EI studies
Kernel functions provide a convenient class of models for a single-peaked
infection response. Figure 1.8 presents three common kernel functions: the Gaussian,
Tricube and Epanechnikov. Each is bounded and symmetric, with a single peak. The
Gaussian kernel approaches zero as the independent variable increases or decreases
without bound, whereas the Tricube and Epanechnikov kernels are identically zero
outside of the interval [-1,1]. Thus all three functions have the characteristic shape of a
single-peaked infection response with a common pre- and post-infection baseline.
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The parameters of these functions correspond to aspects of the infection response
that are typically of focal interest in MC experiments. Consider for instance the Gaussian
kernel, defined by the function
−1

𝑡−𝜇 2

𝐾(𝑡) = (√2𝜋𝜎) 𝑒𝑥𝑝 ( 2𝜎 )

(1.5)

Here 𝜇 represents the time to peak response and 𝜎 can be interpreted as a measure
−1

response duration. By replacing the normalizing constant (√2𝜋𝜎)

with a third

parameter I we obtain a measure of the peak response intensity. By incorporating a
vertical shift parameter B we add the capability of modeling responses with nonzero
baseline values, such as body temperatures. Thus we can modify the basic Gaussian
kernel to obtain a function that directly models the most salient features of the infection
response.
𝑡−𝜇 2

𝐾(𝑡) = 𝐵 + 𝐼 𝑒𝑥𝑝 ( 2𝜎 )

(1.6)

Figure 1.8. Gaussian, Tricube and Epanechnikov kernel functions
One advantage of a compact kernel function such as the tricube is that the
endpoints of the interval on which it takes nonzero values provide direct estimates of the
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timing of response onset and recovery. By allowing for rescaling of both the time and
response variables, we obtain a basic, symmetric tricube kernel response function (1.7).
We explore several variations and extensions of these infection response functions.
3
𝑡−𝑝 3

𝐾(𝑡) = 𝐵 + 𝐼 (1 + |

𝑠

| )

(1.7)

In general, the choice of kernel is an aspect of model specification that the data
analyst must decide upon. The best kernel for the application depends on the shape of the
peaked response as well as the desirability of compactness. Overall, however, we found
that the results were not particularly sensitive to choice of kernel for the applications we
considered. For this reason we do not extensively explore the choice of kernel in this
dissertation. Instead, we give examples of the use of each kernel at various places in the
dissertation: Gaussian kernels are employed in chapters 2 and 3, and a tricube kernel is
used for the viral load modeling of chapter 4. Clearly there are other possible choices of
functions for modeling the infection response trajectories but in this dissertation we
restrict our attention to kernel functions.
1.6. SCOPE AND OUTLINE OF DISSERTATION
Chapter 1 establishes the importance of EI studies for research, epidemiology and
prevention of infectious diseases. Several case studies illustrate the nature of longitudinal
EI data. Traditional approaches to the analysis of this type of data are discussed and an
alternative approach is suggested based on nonlinear hierarchical statistical models.
Chapter 2 considers the case of a symmetric transient response variable, that is, a
variable that can adequately be approximated by a symmetric mean response function.
We introduce a version of the normal-errors NLHM that can be fit using standard
procedures available in several commonly used statistical packages.
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We present a

simulation experiment comparing the performance of our Gaussian nonlinear mixed
model with RM-ANOVA with respect to bias and precision of parameter estimation,
power and Type I error control. Finally we provide an illustrative application to the
equine arteritis virus data from § 1.3.1.
Many responses will not be adequately modeled by a symmetric function. In
Chapter 3 introduces a version of the normal-errors NLHM model suitable for modeling
an asymmetric infection response. We discuss several reasons for preferring to implement
this model as a Bayesian NLHM rather than a nonlinear mixed model. We illustrate the
asymmetric Bayesian NLHM using the equine arteritis virus data from § 1.3.1.
Frequently in MC experiments involving viral pathogens, the focus is the time
course of the viral load in blood, feces or other fluids or excreta. For several reasons the
normal-errors NLHM from Chapters 2 and 3 is not appropriate for modeling viral load.
For the individuals in such experiments, viral load will be exactly zero at all observation
times prior to inoculation. For those in whom the virus is completely cleared, viral load
will return to exactly zero. During infection, however, viral load can be viewed as
fluctuating randomly about some systematic trajectory. Thus the constant variance
assumption is clearly violated. Further, because viral loads are nonnegative it makes no
sense to model a subject’s viral load at each time point as a normal random variable.
Finally, during infection it may happen the variability in viral load increases as the mean
viral load increases. In Chapter 4 we propose an NLHM in which the viral load at each
time point is modeled as a Poisson random variable with mean given by a compact kernel
function. Because the variance of a Poisson random variable is equal to its mean, when
the mean viral load is equal to zero (i.e. pre-onset or post-recovery) the variance will be
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also. Similarly, when the mean viral load is positive (i.e. during infection) the variance
will be positive, and the variance will increase with the mean. We illustrate the viral load
NLHM using the rhinovirus data from § 1.3.2 and the influenza data from § 1.3.3.
1.7. ETHICAL CONSIDERATIONS IN EI STUDIES
Despite their obvious potential benefits for the study of infectious diseases, EI
studies in both humans and animal models raise a host of ethical concerns. There have
been numerous instances of ethically questionable practices involving the use of human
subjects in infectious disease research (Zenilman 2013; Comfort 2009; Krugman 1986).
In the United States, ethical guidelines for research involving human subjects have been
established by the National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research and summarized in its Belmont Report (1979). The
National Institutes of Health have published a framework for evaluating the ethical
aspects of infection-inducing challenge experiments (Miller and Grady 2001). In the
United Kingdom, the Academy of Medical Sciences has published the report Microbial
Challenge Studies in Human Volunteers which provides recommendations and guidance
to ensure the safe and ethical conduct of MCE’s involving human volunteers (2005). The
ethics of EI studies continue to be vigorously debated. Michetti has offered the following
eloquent summary.
Challenge experiments have been an important method of studying the
pathogenesis of many infectious diseases and of evaluating initial efficacy of
vaccines before large scale field tests are conducted. In challenge experiments,
infections are deliberately induced under carefully controlled and monitored
conditions to healthy research volunteers. Induced infections are usually either
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self-limiting or can be fully treated within a short period of time. Because
physicians should be dedicated to alleviating disease and avoiding harm to
patients, this type of experiment may cause uncomfortable symptoms and evoke
serious moral concerns. It should be appreciated however that clinical research
commonly involves risks to subjects that are not outweighed by medical benefits
but are justified by the potential to acquire new knowledge. In that regard,
infection inducing challenges are not necessarily more ethically problematic than
phase I trials aimed at determining maximum tolerated doses of medications. Like
any clinical research, challenge experiments should be conducted by competent
investigators according to sound protocols that incorporate appropriate safeguards
to ensure the safety of volunteers. Because these experiments may provide
valuable information that might not be otherwise obtained, lead to novel
therapies, or speed up vaccine development that will ultimately spare morbidity or
death from infectious diseases and reduce exposure of large groups in field trials,
challenge experiments may be justified. However, the scientific rationale should
be carefully examined for any given pathogen and model. When such a rationale
exists, then the question of risks and discomforts should be addressed (Michetti
2004).
For experiments involving animal subjects, the counterpart to the Institutional
Review Board (IRB) is the Institutional Animal Care and Use Committee (IACUC). The
IACUC has its origins in the Animal Welfare Act passed by the U.S. Congress in 1966.
Today in the U.S. an IACUC is required of all institution that uses animals in federally
funded research. Functions of the local IACUC include review of research protocols and
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evaluation of the care and use of animals (Anderson 2007). A key resource for IACUC’s
is the Guide for the Care and Use of Laboratory Animals, which was published in 1963
by a group of veterinarians known as the Animal Care Panel (Barthold et al. 2011).
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CHAPTER TWO
A nonlinear mixed model for a single-peaked, symmetric response
2.1. INTRODUCTION
Some quantities of interest in the response to an infection, such as body
temperature and lymphocyte counts, fluctuate around a natural baseline value when an
individual is not experiencing infection. The natural baseline level may vary slightly from
one individual to the next. Furthermore, in the infected state, although the mean response
level changes over time the variation about the mean tends to remain relatively consistent
(e.g. Figure 2.2). The normal-errors model introduced in Chapter 1 will often be
appropriate in such cases.
This chapter has three primary aims. First, we present a method for analyzing this
type of longitudinal response data from experimental infection studies using a nonlinear
mixed model (NLMM) that is straightforward to implement in popular statistical software
packages. Second, we illustrate via Monte Carlo simulation the gains in accuracy,
precision and power that this method provides over the traditional method of choice, RMANOVA. Third, we illustrate the application of the model to data from an actual EI
study.
2.2. NORMAL-ERRORS MODEL FOR A SYMMETRIC RESPONSE
Suppose that infection responses for 𝑛 individuals are sampled on multiple
occasions. Let 𝑚𝑖 represent the number of measurement occasions for individual 𝑖 .
(Often in experimental infection studies 𝑚𝑖 is constant across individuals, but we do not
assume it here.) Let 𝑗 index the sampling times 𝑡1, 𝑡2, ⋯ , 𝑡𝑚𝑖 for individual 𝑖. Denote the
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responses for individual 𝑖 as 𝑦𝑖1, 𝑦𝑖2, ⋯ , 𝑦𝑖𝑚𝑖 . We model the individual response profiles
with the modified Gaussian function (1.6).
Level 1 (model of intra-individual variability)
𝑦𝑖𝑗 ~𝑁(𝜇𝑖𝑗 , 𝜎 2 )
𝜇𝑖𝑗 = 𝐵𝑖 + 𝐼𝑖 𝑒𝑥𝑝 [− (

(2.1)
𝑡−𝑝𝑖 2
2𝑠𝑖

) ]

(2.2)

Here 𝐵𝑖 represents the baseline response level for individual 𝑖, 𝑝𝑖 the time to peak
response, and 𝐼𝑖 the peak response intensity. 𝑠𝑖 can be interpreted as a measure of
response duration. A closely related, but more interpretable, measure of response duration
is the full width at half maximum response (FWHM), given by 𝐹𝑊𝐻𝑀𝑖 = 𝑠𝑖 √2ln2. This
is the width of the response curve when the response is halfway between baseline and
peak intensity.
To simplify the notation for Level 2 of the model, we collect the response parameters
for individual 𝑖, into a vector
𝜷𝑖 = [𝐵𝑖 , 𝐼𝑖 , 𝑝𝑖 , log(𝑠𝑖 )]𝑇 .

(2.3)

The scale parameter 𝑠𝑖 is modeled on the log scale to restrict its range to the positive
real numbers. Now suppose that each individual belongs to one of two groups indexed by
𝑔 ∈ {1,2}, and that individual i belongs to group 𝑔. For each group 𝑔 define a population
parameter vector, which is assumed to give rise to the individual response vectors for
members of group 𝑔, as
𝑇

𝜷(𝑔) = [𝐵(𝑔) , 𝐼 (𝑔) , 𝑝(𝑔) , log(𝑠 (𝑔))] .

(2.4)
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2
and denote the variances of the corresponding
Finally let 𝜎𝐵2(𝑔) , 𝜎𝐼2(𝑔) , 𝜎𝑝2(𝑔) , 𝜎log
𝑠 (𝑔)

components of 𝜷(𝑔). Then we specify the mechanism for the inter-individual response
variability as follows.
Level 2 (model of inter-individual variability)
𝜷𝑖 = 𝜷(𝑔) + 𝒃𝑖

(2.5)

2
)
𝒃𝑖 ~𝑁(0, 𝑫(𝑔) ), where 𝑫(𝑔) = diag (𝜎𝐵2(𝑔) , 𝜎𝐼2(𝑔) , 𝜎𝑝2(𝑔) , 𝜎log
𝑠 (𝑔)

(2.6)

A diagonal structure for 𝑫(𝑔) is specified because, due to the modest sample sizes
typical of EI studies, there is usually an insufficient number of individuals to estimate a
full 4 by 4 covariance matrix.
If we had reason to believe that the variance structure were the same in both groups
then we could specify instead
2
𝒃𝑖 ~𝑁(0, 𝑫), where 𝑫 = diag(𝜎𝐵2 , 𝜎𝐼2 , 𝜎𝑝2 , 𝜎log
𝑠)

(2.7)

This is the approach taken in the illustrative example in Section 2.4.
2.2.1. Implementation as a nonlinear mixed model
The model (2.1)-(2.6) can be implemented as a nonlinear mixed model using
widely available statistical computing systems including PROC NLMIXED (Nonlinear
Mixed Models) in SAS, the ‘nlme’ (Linear and Nonlinear Mixed Effects Models)
package in R, and numerous others.
2.3. SIMULATION
In order to assess the performance of the normal-errors NLMM relative to
traditional approaches to modeling experimental infection data, we performed a Monte
Carlo simulation experiment. In the one-sample setting we compared the accuracy and
precision of parameter estimates for the normal-errors NLHM and the one-way RM32

ANOVA, and we computed the coverage rates of estimated confidence intervals for the
parameter estimates from the former. (As we will see in §2.3.2, it is possible in RMANOVA to define ad hoc quantities analogous to the components of 𝜷(𝑔) in the NLMM.
However RM-ANOVA does not provide confidence intervals for those quantities so it is
not possible to assess CI coverage for them.) In the two-sample setting we compared
Type I error control and power for the normal-errors NLMM and the two-way RMANOVA.
2.3.1. Data-generating models
We explored cases where the functional form of the response trajectories is
correctly specified, and also cases where it is not. For the former cases, we first simulated
true parameter vectors 𝜷𝑖 for each individual subject as specified in (2.5)-(2.6), and then
we simulated response profiles for those individuals according to (2.1)-(2.2).
To simulate incorrect specification of the functional form of the responses, we
generated data from a normal-errors model with a parabolic response function (instead of
Gaussian) as summarized in (2.8)-(2.11).
Level 1 (model of intra-individual variability)
𝑦𝑖𝑗 ~𝑁(𝜇𝑖𝑗 , 𝜎 2 )
2
(
)
𝜇𝑖𝑗 = { 𝑎𝑖 (𝑡𝑗 − ℎ𝑖 ) + 𝐵𝑖 − 𝑘𝑖
0

(2.8)
𝑘

if |𝑡𝑗 − ℎ𝑖 | ≤ √𝑎𝑖

𝑖

(2.9)

otherwise

Level 2 (model of inter-individual variability)
𝜷𝑖 = 𝜷(𝑔) + 𝒃𝑖

(2.10)

𝒃𝑖 ~𝑁(0, 𝑫(𝑔) ), where 𝑫(𝑔) = diag(𝜎𝐵2(𝑔) , 𝜎𝑘2(𝑔) , 𝜎ℎ2(𝑔) , 𝜎𝑎2(𝑔) )

(2.11)
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According to this data model, at the individual level, for time points in the interval
[ℎ𝑖 ± √𝑘𝑖 ⁄𝑎𝑖 ] the mean response follows a parabolic trajectory. For time points outside of
this interval, the mean response is equal to 𝐵𝑖 . The population parameters 𝐵, ℎ and 𝑘
correspond, respectively, to 𝐵, 𝑝 and 𝐼 in (2.3) with 𝑘 = −𝐼. The parameter 𝑎 governs the
spread of the parabolic response. Although 𝑎 itself has no direct relationship with 𝑠 in
(2.3), we can directly compare the estimation of response duration by comparing 𝐹𝑊𝐻𝑀,
which for the parabolic response function equals √2𝑘⁄𝑎.
2.3.2. One-sample simulation: method
In the one-sample setting we compared the performance of the normal errors
NLHM with 𝑔 = 1 and the one-way RM-ANOVA model. The latter can be expressed as
in (2.12)-(2.14), with 𝜇 representing the fixed population mean, 𝜋𝑖 a random effect for
subject 𝑖 that does not change with time, and 𝜏𝑗 a fixed effect at time point 𝑗 that is
common to all subjects.
𝑦𝑖𝑗 = 𝜇 + 𝜋𝑖 + 𝜏𝑗 + 𝜀𝑖𝑗

(2.12)

𝜋𝑖 ~𝑁(0, 𝜎𝜋2 )

(2.13)

𝜀𝑖𝑗 ~𝑁(0, 𝜎𝜀2 )

(2.14)

The focus of the one-sample simulation was to compare the accuracy and
precision of estimation of population/fixed effects. We examined four scenarios which
are described in detail below. For each scenario we randomly generated 1,000 data sets
from the appropriate data model (i.e. Gaussian or parabolic). The normal-errors NLMM
(2.1)-(2.6) and one-way RM-ANOVA models (2.12)-(2.14) were then fit to each
simulated data set.
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The means of the population baseline, intensity, time-to-peak and duration
estimates over the 1,000 simulated data sets were calculated for both models, along with
the bias, variance and mean squared error (MSE) for each of the means. For the normalerrors NLHM these quantities are directly estimated by the model. For RM-ANOVA, we
must adopt ad hoc definitions for analogous quantities. The population baseline was
taken to be the estimated response at the first time point, i.e. the estimated intercept. Peak
response intensity was taken to be the difference between the largest estimated mean
response and the baseline. Time to peak response was taken as the time point at which the
group mean peak intensity was observed. FWHM was calculated by locating the time
point on either side of the peak time where the estimated response was nearest in absolute
value to one-half of the estimated peak intensity, and then taking the difference between
those two times.
̅̅̅̅ ) over the 1,000 data sets for the
We also compared the mean standard errors (𝑆𝐸
peak response intensity and FHWM estimates. These estimated standard errors are
readily extracted from the fitted normal-errors NLMM. For RM-ANOVA, these
quantities do not arise naturally from the model and can only be derived from the
simulated data. Specifically, for RM-ANOVA, ̅̅̅̅
𝑆𝐸𝐵̂ was taken to be the standard error of
the estimated mean at the first time point, and ̅̅̅̅
𝑆𝐸𝐼̂ was taken to be the standard error of
the estimated mean at the time point where the peak response was observed.
Model fitting for the normal-errors NLMM was accomplished with the ‘nlme’
package in R (R core team 2012). Initial parameter estimates for ‘nlme’ were set to their
true values from the data generating model. The RM-ANOVA model (2.12)-(2.14) was
fitted via the lme() function in R.
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The default data-generating parameters, unless otherwise specified, were set as
follows.
Level 1 (model of intra-individual variability)
𝜎= 5

(2.15)

Level 2 (model of inter-individual variability)
𝜷 = [20, 30, 50, log(3)]𝑇 i.e. 𝐵 = 20, 𝐼 = 30, 𝑝 = 50, 𝑠 = 3

(2.16)

𝑫 = diag(9, 25, 4, 0.0625) i.e. 𝜎𝐵 = 3, 𝜎𝐼 = 5, 𝜎𝑝 = 2, 𝜎𝑠 = 0.25

(2.17)

The default data collection schedule was every fifth day between days 0 and 40,
then every second day between days 42 and 60, then every fifth time point again between
days 65 and 100. This simulates the approach typically taken in experimental infection
studies, where sampling is more intensive during the period when the response is
expected to occur, and less frequent outside of that interval. We denote this sampling
schedule by a vector 𝒕0 to distinguish it from alternate schedules that were also
considered.
𝒕0 = [0, 5, ⋯ , 35, 40, 42, ⋯ , 58, 60, 65, ⋯ , 100]𝑇

(2.18)

2.3.3. One-sample simulation: results
Effect of sample size on parameter estimation
We simulated sample sizes of n = 5, 15 and 30 subjects while holding the true
population response parameters constant as in (2.15)-(2.17) and the sampling schedule as
in (2.18) Results are summarized in Table 2.1. Several points are noteworthy. 1) The
parameter estimates from the NLMM are more precise at all three sample sizes, with
relative efficiencies ranging from 1.5 to 25.9 in favor the NLMM. The difference in
efficiency was greatest when estimating FWHM, a measure of response duration. The
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efficiency advantage persisted at larger sample sizes. At the smallest sample size (n=5),
neither model precisely estimated intensity (I), but NLMM was nevertheless 2.2 times
more efficient than RM-ANOVA. 2) RM-ANOVA underestimates intensity between
13% and 18%, depending on sample size, and overestimates duration by 21%.
Furthermore, neither bias diminishes as sample size increases, and the underestimation of
intensity actually increases. This demonstrates that there is a systematic bias in the
estimation of response intensity and duration by RM-ANOVA. 3) Both models estimate
baseline and time to peak without bias at all three sample sizes, though again the NLMM
estimates have uniformly greater precision. 4) For n=5, confidence interval coverage
rates for population parameters in the NLMM were well below the nominal rate of 95%
for, but for n=30 coverage was nominal or nearly so. The low coverage rates at small
sample sizes are due largely to the fact that standard error estimates for the population
parameters in the NLMM are conditional upon the variance component estimates. Thus,
the standard error estimates do not reflect the uncertainty in the variance component
estimates. 5) For RM-ANOVA, the average estimated standard error for the population
baseline was more than double the average for NLMM at all three sample sizes, and the
average estimated standard error for the population peak intensity was approximately 1.6
times larger.
Effect of sampling intensity on parameter estimation
Next we fixed the number of subjects at n=10 while varying the sampling
schedule. We compared two schedules with similar numbers of total observations but
different intensities: every third day over the entire study period and every second day
within the true response interval but every fourth day outside the true response interval
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We denote these two schedules by the vectors 𝒕333 and 𝒕424 , which include 34 and 33
sampling occasions respectively.
𝒕333 = [0, 3, 6, ⋯ , 93, 96, 99]𝑇

(2.19)

𝒕424 = [0, 4, 8, ⋯ , 36, 38, 40, ⋯ , 92, 96, 100]𝑇

(2.20)

The MSE’s in Table 2.2 show that estimation of peak intensity and duration were
noticeably better for both models under 𝒕424 , and estimation of time to peak was
improved for RM-ANOVA. Relative efficiencies still strongly favored the NLMM. We
revisit the question of sampling intensity and schedule in Chapter 4.
Effect of inter-individual response variability on parameter estimation
Reports on experimental infection studies often mention considerable variability
in the individual response trajectories, but the effect of this variability on the estimation
of response parameters is rarely addressed. We analyzed the effect of inter-individual
variation in the time to peak response. The number of individuals was held constant at
N=15 and the sampling schedule at 𝒕0 (2.18) while σp was doubled from 2, as in (2.17),
to 4. Results are summarized in Table 2.3. Increasing variability in the time to peak
response negatively affects parameter estimation in both the NLMM and RM-ANOVA.
However the former is far more robust to the increase, as can be seen by comparing the
relative efficiencies of the parameter estimates for σp = 2 and σp = 4. In particular, the
doubling of σp results in a doubling of the underestimation of peak intensity for RMANOVA (from -4.8 to -11.0) and a tripling of the overestimation of FWHM (from 1.4 to
4.4).
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Effect of incorrect response function specification on parameter estimation
Finally we examined performance of the NLMM (2.1)-(2.6) when the true
response function is not Gaussian. To simulate the performance of the NLMM when
correctly specified, the data were generated from the same model (2.1)-(2.6).

To

simulate performance when the response function is incorrectly specified, the data were
generated from the parabolic data model in (2.8)-(2.11) with the following parameters.
Level 1 (model of intra-individual variability)
𝜎= 5

(2.21)

Level 2 (model of inter-individual variability)
𝜷 = [20, −30, 50, −1.2]𝑇 i.e. 𝐵 = 20, 𝑘 = −30, ℎ = 50, 𝑎 = −1.2

(2.22)

𝑫 = diag(9, 25, 4, 0.04) i.e. 𝜎𝐵 = 3, 𝜎𝑘 = 5, 𝜎ℎ = 2, 𝜎𝑎 = 0.2

(2.23)

The value of 𝑎 in (2.23) for the parabolic response function was chosen so as to
make the true FWHM the same as for the Gaussian response. Thus, the Gaussian and
parabolic response functions are essentially identical with respect to baseline, timing of
peak, peak intensity and FWHM. However the Gaussian is considerably wider in the tails
and slightly narrower near the peak. The default sampling schedule 𝒕0 (2.18) was used in
both cases. Results are summarized in Table 2.4.
Comparing the estimated relative efficiencies we see that when the true
underlying response function was parabolic rather than Gaussian, the NLMM was still
much more efficient than RM-ANOVA.
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Table 2.1. Effect of number of subjects on parameter estimation in normal-errors NLMM and one-way RM-ANOVA
n=5
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Parameter
B
Bias
Variance
MSE
CI coverage
I
Bias
Variance
MSE
CI coverage
𝑝
Bias
Variance
MSE
CI coverage
FWHM
Bias
Variance
MSE
CI coverage

NLMM
20.0
-0.03 (0.05)
2.2
2.2
86%
30.1
0.14 (0.09)
8.0
8.0
87%
50.0
0.0 (0.01)
1.0
1.0
86%
7.0
-0.02 (0.02)
0.34
0.34
92%

RM-ANOVA
20.0
-0.02 (0.08)
6.7
6.7
26.1
-3.9 (0.13)
17.5
32.9
50.1
0.07 (0.04)
2.0
2.0
8.5
1.5 (0.09)
8.8
10.9
-

n =15
Relative
efficiency
3.0
2.2
2.025.9
-

NLMM
20.0
0.02 (0.03)
0.7
0.7
93%
30.3
0.32 (0.05)
2.6
2.7
92%
50.0
0.02 (-0.01)
0.3
0.3
93%
7.0
-0.05 (0.01)
0.11
0.11
92%

RM-ANOVA
20.0
0.02 (0.05)
2.3
2.3
25.2
-4.8 (0.08)
6.0
28.8
50.0
0.01 (0.02)
0.7
0.7
8.5
1.4 (0.03)
1.1
3.0
-

n =30
Relative
efficiency
3.3
2.3
2.3
10.0
-

NLMM
20.0
-0.02 (0.02)
0.4
0.4
95%
30.3
0.32 (0.04)
1.4
1.5
94%
50.0
-0.01 (0.01)
0.15
0.15
92%
7.0
-0.05 (0.01)
0.06
0.06
92%

RM-ANOVA
20.0
0.0 (0.04)
1.2
1.2
24.9
-5.1 (0.06)
3.5
29.4
50.0
-0.03 (0.02)
0.23
0.23
8.4
1.3 (0.03)
0.7
2.3
-

Relative
efficiency
3.0
2.5
1.5
11.7
-

̅̅̅̅𝐵
1.3 (0.01)
3.2 (0.01)
0.8 (0.0)
1.9 (0.0)
0.6 (0.0)
1.3 (0.0)
𝑆𝐸
̅̅̅̅𝐼
2.5 (0.03)
4.1 (0.02)
1.5 (0.01)
2.4 (0.01)
1.1 (0.0)
1.7 (0.0)
𝑆𝐸
B represents the population mean baseline level; I represents the population mean peak response intensity; 𝑝 represents the population mean time to
peak response; and FWHM represents the population mean full width at half maximum, which is a measure of the duration of the infection response.

-

Table 2.2. Effect of sampling intensity on parameter estimation in NLMM
and one-way RM-ANOVA
Sampling schedule

𝒕333
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Parameter
𝐵
Bias
Variance
MSE
𝐼
Bias
Variance
MSE
𝑝
Bias
Variance
MSE
𝐹𝑊𝐻𝑀
Bias
Variance
MSE

NLMM
20.0
-0.07 (0.03)
0.98
0.99
30.5
0.54 (0.07)
4.8
5.1
50.0
-0.01 (0.02)
0.44
0.44
7.0
-0.07 (0.02)
0.24
0.25

RM-ANOVA
20.0
-0.03 (0.06)
3.5
3.5
24.7
-5.3 (0.09)
8.8
36.9
50.2
0.21 (0.04)
1.8
1.8
8.9
1.8 (0.06)
3.9
7.2

𝒕424
Relative
efficiency
3.5
7.2
4.1
28.9

NLMM
20.0
0.02 (0.03)
0.94
0.94
30.3
0.28 (0.06)
4.0
4.1
50.0
0.01 (0.02)
0.48
0.48
7.0
-0.04 (0.01)
0.15
0.16

RM-ANOVA
20.1
0.09 (0.06)
3.4
3.4
25.4
-4.6 (0.09)
9.0
30.4
50.0
0.03 (0.03)
1.1
1.1
8.5
1.4 (0.04)
1.5
3.5

Relative
efficiency
3.8
7.4
2.3
21.9

̅̅̅̅
0.9 (0.01)
2.1 (0.0)
0.93 (0.01)
2.2 (0.01)
𝑆𝐸𝐵
̅̅̅̅
2.0 (0.01)
2.6 (0.01)
1.85 (0.01)
2.8 (0.01)
𝑆𝐸𝐼
B represents the population mean baseline level; I represents the population mean peak response intensity; 𝑝
represents the population mean time to peak response; and FWHM represents the population mean full width
at half maximum, which is a measure of the duration of the infection response.

Table 2.3. Effect of variability in time to peak response on parameter
estimation in one-sample NLMM and one-way RM-ANOVA
𝜎𝑝 = 2
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Parameter
B
Bias
Variance
MSE
I
Bias
Variance
MSE
𝜇
Bias
Variance
MSE
FWHM
Bias
Variance
MSE

NLMM
20.0
0.02 (0.03)
0.7
0.7
30.3
0.32 (0.05)
2.6
2.7
50.0
0.02 (-0.01)
0.3
0.3
7.0
-0.05 (0.01)
0.11
0.11

RM-ANOVA
20.0
0.02 (0.05)
2.3
2.3
25.2
-4.8 (0.08)
6.0
28.8
50.0
0.01 (0.02)
0.7
0.7
8.5
1.4 (0.03)
1.1
3.0

𝜎𝑝 = 4
Relative
efficiency
3.3
10.7
2.3
27.3

NLMM
20.1
0.14 (0.03)
0.74
0.8
28.9
-1.13 (0.08)
7.0
8.3
49.9
-0.06 (0.04)
1.3
1.3
7.1
-0.01 (0.01)
0.22
0.22

RM-ANOVA
20.0
-0.01 (0.05)
2.2
2.2
19.0
-11.0 (0.1)
8.1
128.2
49.9
-0.1 (0.1)
3.7
3.7
11.5
4.4 (0.07)
4.7
24.4

Relative
efficiency
2.8
15.4
2.8
111.0

̅̅̅̅𝐵
0.8 (0.0)
1.9 (0.0)
0.8 (0.0)
2.2 (0.0)
𝑆𝐸
̅̅̅̅𝐼
1.5 (0.01)
2.4 (0.01)
2.1 (0.03)
2.9 (0.01)
𝑆𝐸
B represents the population mean baseline level; I represents the population mean peak response intensity; 𝑝
represents the population mean time to peak response; and FWHM represents the population mean full width
at half maximum, which is a measure of the duration of the infection response.

Table 2.4. Comparison of NLMM and RM-ANOVA when NLMM response function
is incorrectly specified
Gaussian response
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Parameter
B
Bias
Variance
MSE
I
Bias
Variance
MSE
𝜇
Bias
Variance
MSE
FWHM
Bias
Variance
MSE

NLMM
20.0
0.02 (0.03)
0.7
0.7
30.3
0.32 (0.05)
2.6
2.7
50.0
0.02 (-0.01)
0.3
0.3
7.0
-0.05 (0.01)
0.11
0.11

RM-ANOVA
20.0
0.02 (0.05)
2.3
2.3
25.2
-4.8 (0.08)
6.0
28.8
50.0
0.01 (0.02)
0.7
0.7
8.5
1.4 (0.03)
1.1
3.0

Parabolic response
Relative
efficiency
3.3
10.7
2.3
27.3

NLMM
19.8
-0.2 (0.03)
0.7
0.7
32.5
2.5 (0.06)
3.4
9.9
50.0
-0.02 (0.02)
0.3
0.3
6.2
-0.9 (0.01)
0.1
0.9

RM-ANOVA
20.1
-0.08 (0.05)
2.3
2.3
25.5
-4.5 (0.08)
4.9
25.1
50.0
0.03 (0.02)
0.6
0.6
7.9
0.8 (0.03)
0.8
1.5

Relative
efficiency
3.3
2.8
2.0
1.7

̅̅̅̅
0.8 (0.0)
1.9 (0.0)
0.8 (0.0)
2.0 (0.0)
𝑆𝐸𝐵
̅̅̅̅𝐼
1.5 (0.01)
2.4 (0.01)
1.8 (0.01)
2.6 (0.01)
𝑆𝐸
B represents the population mean baseline level; I represents the population mean peak response
intensity; 𝑝 represents the population mean time to peak response; and FWHM represents the population
mean full width at half maximum, which is a measure of the duration of the infection response.

2.3.4. Two-sample simulation: method
We next compared the performance of the normal errors NLMM model with
𝑔 ∈ {1,2}, i.e. the two-sample NLMM model, with the two-way RM-ANOVA model.
The latter can be expressed as follows, with 𝜇 representing a fixed population mean, 𝛾𝑔 a
fixed effect for group 𝑔 that is common to all time points, 𝜏𝑗 a fixed effect at time point 𝑗
that is common to all subjects, (𝛾𝜏)𝑔𝑗 a fixed effect unique to the members of group 𝑔
that is specific to time 𝑗, and 𝜋(𝑖)𝑔 a random effect for subject 𝑖 within group 𝑔 that does
not change with time.
𝑌𝑖𝑔𝑗 = 𝜇 + 𝛾𝑔 + 𝜏𝑗 + (𝛾𝜏)𝑔𝑗 + 𝜋𝑖(𝑔) + 𝜀𝑖𝑔𝑗

(2.24)

𝜋𝑖(𝑔) ~𝑁(0, 𝜎𝜋2 )

(2.25)

𝜀𝑖𝑔𝑗 ~𝑁(0, 𝜎𝜀2 )

(2.26)

2
𝑚
∑2𝑔=1 𝛾𝑔 = 0, ∑𝑚
𝑗=1 𝜏𝑗 = 0, ∑𝑔=1(𝛾𝜏)𝑔𝑗 = 0, ∑𝑗=1(𝛾𝜏)𝑔𝑗 = 0

(2.27)

In (2.27), 𝑚 represents the final measurement occasion which, in the simulations,
is the same for all individuals. The findings on parameter estimation from the one-sample
simulation carry over to estimation in the two-sample setting. Our focus for the twosample case, therefore, was a comparison of power and Type I error control for testing
the null hypothesis of no difference between the true group infection responses. For RMANOVA this amounts to the hypothesis that the time-specific group effects are equal at
all measurement occasions, i.e.
𝐻0 : (𝛾𝜏)1𝑗 = (𝛾𝜏)2𝑗 for all 𝑗

(2.28)

We fit the two-sample RM-ANOVA model (2.24)-(2.27) and conducted the
hypothesis test (2.28) using both the traditional approach, implemented in R by the
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function aov() within the ‘stats’ package, and a mixed model approach using the R
function lme() within the ‘nlme’ package, respectively.
For the NLMM (2.1)-(2.6) the hypothesis of no difference in the mean population
infection responses can be expressed as
𝐻0 : 𝐼 (1) = 𝐼 (2) and 𝑝(1) = 𝑝(2) and 𝑠 (1) = 𝑠 (2) .

(2.29)

Following the recommendation of Pinheiro and Bates (2000) we tested this hypothesis
via conditional F test.
Data were generated for each group independently using the same process
described for the one-sample simulation.
2.3.5. Two-sample simulation: results
Type I error control for test of no difference in group responses
Response data for both groups were generated using the parameter values in
(2.15)-(2.17) so that there was, in fact, no difference in the population infection
responses. The experiment was repeated for group sizes ranging from N=5 to N=100
individuals. At each sample size 1,000 data sets were generated using both the Gaussian
response function (2.2) and the parabolic response function (2.9). The hypotheses (2.28)
and (2.29) were tested as describe above and the proportion of Type I errors was
computed for each method along with 95% Clopper-Pearson confidence intervals. Thus
we examined the Type I error rates for NLHM and RM-ANOVA at six different sample
sizes when the response function in the NLHM was correctly specified and when it was
incorrectly specified.
Results are summarized in Table 2.5. We consider first the case when the true
response function was Gaussian. For larger sample sizes (n =15, n =30) the Type I error
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rate was near the nominal rate for both NLMM and RM-ANOVA [aov()
implementation). However for smaller sample sizes (n =5, n =10) the Type I error rate for
RM-ANOVA was nearly twice the nominal rate and for NLMM it was two to three times
higher. When the true response function was parabolic, NLMM was not much affected.
However RM-ANOVA fared slightly worse at all sample sizes.
For the lme() implementation of RM-ANOVA, the rate remained two to three
times above the nominal rate across all sample sizes from n=5 to n=100, irrespective of
the true shape of the response function.
Table 2.5. Type I error rate by sample size for NLMM and RM-ANOVA
n
5
10
15
30
50
100

Gaussian data model
NLMM
RMLMM
ANOVA
0.15
0.09
0.13
(0.13, 0.18) (0.07, 0.11) (0.10, 0.15)
0.10
0.07
0.15
(0.08, 0.12) (0.06, 0.09) (0.12, 0.17)
0.09
0.07
0.12
(0.07, 0.11) (0.05, 0.08) (0.10, 0.14)
0.08
0.07
0.15
(0.06, 0.09) (0.06, 0.09) (0.13, 0.18)
0.06
0.07
0.13
(0.04, 0.07) (0.05, 0.08) (0.11, 0.15)
0.05
0.06
0.13
(0.04, 0.07) (0.05, 0.08) (0.11, 0.16)

Parabolic data model
NLMM
RMLMM
ANOVA
0.15
0.11
0.16
(0.12, 0.17) (0.09, 0.13) (0.13, 0.18)
0.09
0.09
0.14
(0.07, 0.11) (0.07, 0.10) (0.12, 0.16)
0.07
0.08
0.13
(0.05, 0.08) (0.06, 0.10) (0.11, 0.15)
0.05
0.08
0.13
(0.04, 0.07) (0.06, 0.10) (0.11, 0.16)
0.05
0.09
0.15
(0.04, 0.07) (0.07, 0.11) (0.13, 0.17)
0.04
0.08
0.14
(0.03, 0.05) (0.06, 0.10) (0.12, 0.17)

Power to detect a true difference in group responses
To investigate the power of NLHM and RM-ANOVA to detect true differences in
population infection responses between groups, we considered three scenarios:
𝐼 (1) ≠ 𝐼 (2) , 𝑝(1) = 𝑝(2) , 𝑠 (1) = 𝑠 (2)

(2.30)

𝐼 (1) = 𝐼 (2) , 𝑝(1) ≠ 𝑝(2) , 𝑠 (1) = 𝑠 (2)

(2.31)

𝐼 (1) = 𝐼 (2) , 𝑝(1) = 𝑝(2) , 𝑠 (1) ≠ 𝑠 (2)

(2.32)
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A

B

C

Figure 2.1. Population response curves for two-sample simulation. (A) Peak intensity:
𝐼 (1) = 30 vs. 𝐼 (2) = 36. (B) Response duration: 𝑠 (1) = 2.5 vs. 𝑠 (2) = 3 [𝐹𝑊𝐻𝑀 (1) = 5.9
vs. 𝐹𝑊𝐻𝑀 (2) = 7.1 days]. (C) Time to peak: 𝑝(1) = 49 vs. 𝑝(2) = 51 days.
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As in the Type I error experiment we began with the true parameter values for
both groups specified as in (2.15)-(2.17). For scenario (2.30), we increased I (2) from 30
to 36; for scenario (2.31) we decreased p(1) to 49 and increased p(2) to 51; and for
scenario (2.32) we decreased s (1) from 3 to 2.5, which is equivalent to decreasing
FWHM (1) from 7.1 days to 5.9 days. The three scenarios are visualized in Figure 2.1.
Table 2.6. Effect of number of subjects on power to detect a true difference
in response to infection in two-sample NLMM and two-way RM-ANOVA
Sample size
Parameter and model

n=5

n =15

n =30

NLHM

0.40 (0.37, 0.43)

0.64 (0.61, 0.67)

0.92 (0.90, 0.93)

RM-ANOVA – aov()

0.14 (0.12, 0.17)

0.23 (0.20, 0.26)

0.42 (0.40, 0.45)

RM-ANOVA – lme()

0.21 (0.18, 0.23)

0.35 (0.32, 0.38)

0.57 (0.54, 0.60)

NLHM

0.43 (0.40, 0.46)

0.71 (0.68, 0.73)

0.94 (0.92, 0.95)

RM-ANOVA - aov()

0.10 (0.08, 0.12)

0.11 (0.09, 0.13)

0.19 (0.16, 0.21)

RM-ANOVA – lme()

0.18 (0.15, 0.20)

0.20 (0.18, 0.23)

0.32 (0.30, 0.35)

NLHM

0.39 (0.36, 0.42)

0.67 (0.64, 0.70)

0.91 (0.89, 0.92)

RM-ANOVA – aov()

0.37 (0.34, 0.40)

0.74 (0.71, 0.77)

0.96 (0.94, 0.97)

RM-ANOVA – lme()

0.45 (0.41, 0.48)

0.82 (0.79, 0.84)

0.97 (0.96, 0.98)

Peak intensity (𝐼)

Response duration (𝐹𝑊𝐻𝑀)

Time to peak intensity (𝑝)

For all scenarios we estimated the power of each method at three sample sizes
(N=5, 15, 30). At each sample size 1,000 data sets were generated using both the
Gaussian response function (2.2) and the parabolic response function (2.9). The
hypotheses (2.28) and (2.29) were tested as described above and power was estimated as
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the proportion of data sets for which the null hypothesis was correctly rejected, along
with 95% Clopper-Pearson confidence intervals. The two data models correspond to
correct and incorrect specification of the mean response function for the NLHM.
Results are summarized in Table 2.6. We find that the NLMM, when correctly
specified, has between two and six times the power of RM-ANOVA to detect a true
difference in response duration or intensity at sample sizes ranging from n=5 to n =30.
Interestingly, RM-ANOVA outperformed the NLMM by a modest amount for detecting a
difference in time to peak. Misspecifying the response function as Gaussian when it was
truly parabolic did not adversely affect power (Table 2.7).
Table 2.7. Effect of number of subjects on power to detect a true difference in response
to infection in two-sample NLMM and two-way RM-ANOVA – NLMM mean response
function incorrectly specified
Sample size
Parameter and model

n =5

n =15

n =30

NLHM

0.44 (0.41, 0.47)

0.73 (0.70, 0.76)

0.96 (0.95, 0.97)

RM-ANOVA – aov()

0.18 (0.15, 0.20)

0.36 (0.33, 0.39)

0.64 (0.61, 0.67)

RM-ANOVA – lme()

0.25 (0.22, 0.28)

0.47 (0.44, 0.50)

0.75 (0.73, 0.78)

NLHM

0.39 (0.35, 0.42)

0.67 (0.64, 0.70)

0.95 (0.93, 0.96)

RM-ANOVA – aov()

0.10 (0.08, 0.12)

0.14 (0.12, 0.16)

0.23 (0.21, 0.25)

RM-ANOVA – lme()

0.16 (0.14, 0.18)

0.24 (0.21, 0.26)

0.35 (0.32, 0.40)

NLHM

0.39 (0.35, 0.42)

0.62 (0.59, 0.65)

0.91 (0.89, 0.92)

RM-ANOVA – aov()

0.36 (0.33, 0.39)

0.77 (0.74, 0.79)

0.95 (0.94, 0.97)

RM-ANOVA – lme()

0.45 (0.41, 0.48)

0.83 (0.80, 0.85)

0.98 (0.97, 0.99)

Peak intensity (𝐼)

Response duration (𝐹𝑊𝐻𝑀)

Time to peak intensity (𝑝)
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2.4. ILLUSTRATIVE EXAMPLE
Referring to the EAV case studies from Chapter 1, we compare the population
febrile responses to the Bucyrus and Kentucky-84 strains of EAV. In the experiments by
Go and Campos, core body temperature (CBT) was observed on days -7, -4 and -2 prior
to inoculation and on days 0, 2, 4, 6, 8, 10, 12 and 14 post-inoculation (DPI). Go et al
challenged eight mares with the Bucyrus strain whereas Campos et al challenged eight
stallions with the KY-84 strain. Figure 4 presents the observed, subject-specific febrile
response profiles for the two groups.

Figure 2.2. Observed febrile response profiles for eight mares challenged with the
Bucyrus strain of EAV, and eight stallions challenged with the Kentucky-84 strain
All sixteen profiles display a single-peaked response with a common pre- and
post-infection baseline body temperature. We modeled the febrile responses using the
NLHM in (2.1)-(2.7) with 𝑔 ∈ {1,2}. The estimate of 𝜎log(𝑠) was essentially zero,
suggesting no need to include subject-specific scale parameters in the model. We refit the
model with the scale parameters treated as purely fixed effects. Diagnostic checks did not
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indicate any violations of distributional assumptions (see supplemental plots in Appendix
A). The posterior estimates are summarized in Table 2.8.
Table 2.8. Estimates of population febrile response parameters following challenge of
eight mares with Bucyrus strain of EAV and eight stallions with KY-84 strain
Bucyrus strain (mares)
Parameter
Estimate 95% CI
Population infection response parameters
99.4
(99.1, 99.7)
𝐵(1)
3.3
(2.8, 3.8)
𝐼 (1)
(1)
6.3
(6.0, 6.6)
𝑝
(1)
0.86
(0.71, 1.02)
log(𝑠)
Variance components
0.33
(0.20, 0.56)
𝜎𝐵
0.47
(0.22, 0.99)
𝜎𝐼
0.23
(0.09, 0.57)
𝜎𝑝
0.82
(0.75, 0.89)
𝜎

KY-84 strain (stallions)
Parameter
Estimate 95% CI
𝐵(2) − 𝐵(1)
𝐼 (2) − 𝐼 (1)
𝑝(2) − 𝑝(1)
log 𝑠 (2) − log 𝑠 (1)

-0.03
1.3
-0.6
-0.05

(-0.50, 0.43)
(0.6, 2.0)
(-1.1, -0.2)
(-0.24, 0.14)

The population parameters characterize the mean response to inoculation with the
Bucyrus strain of EAV in mares (superscript 𝑔 = 1) and the KY-84 strain in stallions
(superscript 𝑔 = 2 ). (More precisely, they represent the mean infection response
parameter values for the populations from which the samples were drawn. If the samples
were selected at random from a well-defined population then the posterior means can be
interpreted as estimates of the true mean values within the source population.) The
estimates of baseline CBT differ by only 0.03 ℉ (-0.50, 0.43), as might be expected. The
duration of fever was similar also, with the scale parameter estimates differing by -0.05 (0.24, 0.14) units on the log scale. This translates to a difference in FWHM of 0.3 (-0.8,
1.2) days. However they differed with respect to peak fever intensity and time to peak
fever. On average, in the stallions challenged with the KY-84 strain, the febrile response
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peaked 0.6 (-1.1, -0.2) days earlier with a maximum intensity 1.3 (0.6, 2.0) degrees
higher. The 95% confidence intervals suggest that the true differences in significantly
different than zero. Figure 2.3 illustrates the population febrile response curves for the
two groups.

Figure 2.3. Population febrile response curves for mares challenged with the Bucyrus
strain of EAV, and stallions challenged with the Kentucky-84 strain
Formally testing the hypothesis of no difference in population infection responses
(2.29) with a conditional F test, we find evidence in favor of rejecting [F=7.1, p=0.0001,
df=(3,265)]. Furthermore, testing hypothesis (2.28) with the two-way RM-ANOVA
model (2.24)-(2.26) leads to the same conclusion (F=4.3, p<0.0001).
The variance component estimates quantify the extent to which individual febrile
responses may vary about their group’s population response. Thus for example, for a
particular mare from the source population inoculated with the Bucyrus strain of EAV, it
would be quite unusual to observe a fever that peaked at less than 𝐼 (1) − 1.96𝜎𝐼 = 2.4℉
above baseline CBT or at higher than

𝐼 (1) + 1.96𝜎𝐼 = 4.2℉ above baseline. The

estimates of 𝜎𝐵 and 𝜎𝑝 have similar interpretations.
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2.5. DISCUSSION
In this chapter we proposed a nonlinear mixed model (2.1)-(2.6) suitable for
modeling a continuous, longitudinal response variable having normally distributed errors
with constant variance across all measurement occasions. Example of such responses
include quantities such as body temperature and lymphocyte counts. The model assumes
that the systematic portion of the intra-individual response variation follows a Gaussian
trajectory. Thus it is appropriate for situations in which the individual responses are
approximately symmetric about a single peak. Implementation is straightforward using
the NLMM framework (Lindstrom and Bates 1990, Davidian and Giltinan 1995)
available in many standard software packages.
We proposed this model as an alternative to RM-ANOVA, which has traditionally
been the most commonly used method of analyzing longitudinal response data from EI
studies. The primary difference between the two approaches is that RM-ANOVA treats
the responses at each time point as if they were unrelated to one another, whereas the
NLMM models the relationship among the responses across time points through
individual mean response functions (2.2). One consequence is that in RM-ANOVA each
additional measurement occasion increases by one the number of degrees of freedom
used to estimate the model. By contrast, the number of degrees of freedom in estimating
the NLHM does not depend on the number of time points observed. We hypothesized
that this difference would result in less efficient estimation of model parameters for RMANOVA, particularly when the number of measurement occasions is large. Another
advantage of the NLMM is that its parameters represent aspects of the infection response
of inherent biological interest: baseline, time to peak response, peak intensity and
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response duration. In RM-ANOVA such quantities can only be approximated by ad-hoc
methods.
2.5.1. Simulation: estimation
We tested our primary hypothesis via Monte Carlo simulation experiments.
Simulation results indicated that the NLHM substantially outperformed RM-ANOVA
across a broad range of scenarios, and that under certain conditions the improvement can
be enormous. We found estimation in the NLHM to be more precise than RM-ANOVA
for all model parameters, and less biased for peak intensity and duration parameters.
We also demonstrated the effect of increased inter-individual response variability
on parameter estimation. It seems self-evident to us that, unless there is very little
variation in the timing of the individual peaks, any approach that involves naïvely
averaging a group of single-peaked response profiles in a pointwise manner will result in
understated peak intensity and overstated response duration. When the individual peaks
occur at different times the effect will be to dampen the estimate of the population peak
intensity. Further, the occurrence of even a small number of responses of unusually long
duration will give the appearance, under pointwise averaging, that the population
response duration is longer than it truly is. This effect has been noted recently in an EI
study by DeVincenzo and colleagues (2010). Specifically, in studying viral loads in
subjects experimentally challenged with respiratory synctitial virus, they point out that
when the individual viral load curves are naïvely averaged the breadth (duration) of the
resulting population curves is misleadingly wide, and the magnitude (intensity)
misleadingly low. (They attempted to correct for this effect by adjusting the individual
viral load curves based on an arbitrary “incubation time”. Our method requires no such
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ad-hoc adjustment.) Our simulation experiment confirmed that increasing variability in
the time to peak response negatively affects parameter estimation in both the NLMM and
RM-ANOVA, but that the former is far more robust to the increase.
Finally, we explored the effect of incorrect specification of the mean response
function on parameter estimation. We found that when the true underlying response
function was parabolic rather than Gaussian, the NLMM was still considerably more
efficient than RM-ANOVA.
2.5.2. Simulation: type I error control and power
When the number of subjects per group was 5, the Type I error rate for RMANOVA was nearly twice the nominal rate and for NLMM it was three times the
nominal rate. For 𝑛=10 the Type I error rate for NLMM was still twice nominal. These
results suggest that experimental infection studies with small numbers of individuals per
group – which appear to be the norm in the literature – are subject to higher-than-nominal
Type I error rates, with either NLMM or RM-ANOVA.
Our power analysis indicates that in certain scenarios the NLMM provides a large
increase in power over RM-ANOVA with comparable Type I error control. In our
simulation, in all scenarios the NLMM achieved 80% power to detect differences in
response duration and peak intensity with somewhere between 15 and 30 subjects per
group. By contrast, with 30 subjects per group RM-ANOVA achieved only 42% power
for a true difference in peak intensity and 19% power for a true difference in response
duration.
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2.5.3. Illustrative example
When applied to the EAV febrile response data, both the NLMM and RMANOVA detected a significant difference in the mean population febrile response of
mares challenged with the recombinant Bucyrus strain compared to the response of
stallions challenged with the KY-84 strain. Judging from Figure 2.3, the essential
difference between the febrile responses appears to be in intensity of the peak. For the
simulated data the relative change in intensity was
febrile response data we can estimate

4.6−3.3
3.3

𝐼 (2) −𝐼 (1)
𝐼 (1)

=

36−30
30

= 0.2, and for the

= 0.39. In other words, in the febrile

response data we were searching for a relative change that was twice the size of the
relative change in the simulated data. In this case the change was large enough to be
detected by either method.
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CHAPTER THREE
A Bayesian hierarchical model for a single-peaked, asymmetric infection response
3.1. INTRODUCTION
In Chapter 2 we presented the normal-errors NLHM as an alternative to repeated
measures analysis of variance (RM-ANOVA) for analyzing time course data from
experimental infection studies. We demonstrated, via Monte Carlo simulation
experiments, scenarios in which the NLHM provides more accurate and precise
estimation of population parameters, and greater power for detecting group differences,
than RM-ANOVA. Furthermore, at moderate-to-large sample sizes (N=15 or greater) it
provides near-nominal Type I error control.
Chapter 2 focused on the case of a symmetric response. The symmetric model
was implemented as a nonlinear mixed model (NLMM) (Sheiner et al 1972, Lindstrom
and Bates 1990, Davidian and Giltinan 1995, Vonesh and Chinchilli 1997). One
attractive feature of this approach is the availability of several widely used software
packages for fitting NLMM’s. However it is important to note that maximum likelihood
estimation and inference for NLMM’s are based on asymptotic results which are not
guaranteed to hold for the relatively small sample sizes typical of EI studies.
In the present chapter we consider asymmetric responses within the context of the
normal-errors NLHM. A Bayesian approach to model implementation is introduced in
part to avoid the large-sample assumptions of the NLMM approach, but it proves to have
several additional benefits which we discuss.
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3.2. NORMAL-ERRORS NLHM FOR AN ASYMMETRIC RESPONSE
3.2.1. Modeling an asymmetric infection response
In Chapter 2 we introduced a model for a symmetric infection response based on a
Gaussian mean response function:
𝑡−𝑝 2

𝑓 (𝑡) = 𝐵 + 𝐼 ∗ 𝑒𝑥𝑝 [− ( 2𝑠 ) ]

(3.1)

One way to extend this model to accommodate asymmetric responses is to replace
(3.1) with a piecewise function consisting of two half-Gaussian curves that are given
different scale parameters but constrained to meet at their peaks, as in (3.2).
(𝑡−𝑝)2

𝐵 + 𝐼 ∗ 𝑒𝑥𝑝 [− 2𝑙2 ] , 𝑡 ≤ 𝑝
𝑓 (𝑡 ) = {
(𝑡−𝑝)2
], 𝑡 > 𝑝
𝐵 + 𝐼 ∗ 𝑒𝑥𝑝 [−
2

(3.2)

2𝑟

The interpretations of the parameters 𝐵, 𝐼 , and 𝑝 are unchanged. The scale
parameters l and r can be interpreted, respectively, as measures of the duration of the
onset and recovery phases of infection. If more interpretable measures of these quantities
are desired, l and r are directly proportional to the half-widths at half-maximum intensity
(HWHM): 𝐻𝑊𝐻𝑀𝑙 = 𝑙√2ln2 and 𝐻𝑊𝐻𝑀𝑟 = 𝑟√2ln2. The full width at half-maximum
intensity (FWHM) can be interpreted as an index of total response duration: 𝐹𝑊𝐻𝑀 =
𝐻𝑊𝐻𝑀𝑙 + 𝐻𝑊𝐻𝑀𝑟 = (𝑙 + 𝑟)√2ln2 . Figure 3.1 demonstrates the flexibility of the
piecewise half-Gaussian function to describe a wide range of response trajectories. Other
applications of piecewise functions in nonlinear regression models have been described
by Huisman (1993), Mü ller (1997) and Gö ssl (2001).
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Figure 3.1. Response shapes accommodated by a piecewise Gaussian function
3.2.2. Statement of the model
We are now in a position to state the normal-errors NLHM for an asymmetric
infection response, using a piecewise Gaussian kernel for the mean response function.
Suppose that infection responses for 𝑛 individuals selected at random from a target
population have been sampled on multiple occasions. For generality we allow the number
of observations to vary among individuals and we denote by 𝑚𝑖 the number of sampling
occasions for individual 𝑖. Let 𝑗 index the sampling times 𝑡1, 𝑡2, ⋯ , 𝑡𝑚𝑖 for individual and
denote the responses for individual 𝑖 as 𝑦𝑖1, 𝑦𝑖2, ⋯ , 𝑦𝑖𝑚𝑖 .

59

Level 1 (model of intra-individual variability)
𝑦𝑖𝑗 ~𝑁(𝜇𝑖𝑗 , 𝜎 2 )
𝐵𝑖 + 𝐼𝑖 𝑒𝑥𝑝 [−
𝜇𝑖𝑗 =

𝐵𝑖 + 𝐼𝑖 𝑒𝑥𝑝 [−
{

(3.3)
(𝑡𝑗 −𝑝𝑖 )2
2𝑙𝑖2
(𝑡𝑗 −𝑝𝑖 )2
2𝑟𝑖2

] , 𝑡𝑗 ≤ 𝑝𝑖
(3.4)

] , 𝑡𝑗 > 𝑝𝑖

Level 2 (model of inter-individual variability)
𝜷𝑖 = 𝜷(𝑔) + 𝒃𝑖

(3.5)

2
)
, 𝜎2
𝒃𝑖 ~𝑁(0, 𝑫(𝑔) ), where 𝑫(𝑔) = diag (𝜎𝐵2(𝑔) , 𝜎𝐼2(𝑔) , 𝜎𝑝2(𝑔) , 𝜎log
𝑙(𝑔) log 𝑟 (𝑔)

(3.6)

The scale parameters 𝑙𝑖 and 𝑟𝑖 are modeled on the log scale to restrict their ranges to
the positive real numbers. As in Chapter 2, we assume that individual 𝑖 belongs to group
𝑔, where 𝑔 ∈ {1,2}, and that 𝜷𝑖 and 𝜷(𝑔) are defined as follows.
𝜷𝑖 = [𝐵𝑖 , 𝐼𝑖 , 𝑝𝑖 , log(𝑙𝑖 ), log(𝑟𝑖 )]𝑇 .

(3.7)

𝜷(𝑔) = [𝐵(𝑔) , 𝐼 (𝑔) , 𝑝(𝑔) , log 𝑙 (𝑔) , log 𝑟 (𝑔) ]

𝑇

(3.8)

If there is reason to think that the inter-individual variability is not significantly
different between the two groups then in 3.6 we can alternatively specify that 𝑫(𝑔) =
2
2
diag(𝜎𝐵2 , 𝜎𝐼2 , 𝜎𝑝2 , 𝜎log
𝑙 , 𝜎log 𝑟 ).

3.2.3. Bayesian implementation
In principle the NLHM (3.3)-(3.8) may be implemented within either a frequentist
or Bayesian framework. We pursued a Bayesian approach in part to avoid the largesample assumptions of the NLMM approach, but there are numerous additional benefits.
Model specification is entirely under the control of the analyst. This can simplify
diagnosis of the convergence problems that often arise in NLHM’s with small samples. It
also provides finer control over the details of model specification than may be possible in
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many off-the-shelf software packages. Furthermore, calculation of various secondary
quantities of interest, such as credible intervals on mean response curves and timing of
response onset and recovery, is straightforward.
A Bayesian perspective considers the model parameters 𝜷, 𝜎 and 𝑫 not as fixed,
unknown quantities, but as random variables with probability distributions. The
investigator’s a priori knowledge about the likely values of these parameters is specified
by prior distributions 𝑝(𝜷), 𝑝(𝜎) and 𝑝(𝑫). The joint posterior distribution of the model
parameters is obtained via Bayes’ Theorem, which updates the prior based on the
likelihood of the observed data obtained from the EI study (LeSaffre and Lawson 2012).
Inference is then based on the resulting joint posterior distribution of 𝜷, 𝜎 and 𝑫.
We specified uniform priors of the form (0,c) for the residual standard deviation 𝜎
and for all standard deviation parameters in 𝑫, thus reflecting vague prior knowledge
about their likely values. Gelman (2006) has recommended uniform priors of this form
for the variance component parameters in hierarchical models over the more traditional
choices of inverse Gamma and Wishart priors. For the population infection response
parameters in 𝜷 we also specified uniform (0,c) priors for the scale parameters log 𝑙 and
log 𝑟, the intensity parameter I, and the time to peak parameter 𝑝. Finally we specified a
uniform (a,b) prior for the baseline parameter 𝐵. The constants a, b and c reflect bounds
on the plausible population mean values. Gaussian priors with large variances are often
used for population parameters in hierarchical models (LeSaffre and Lawson 2012). This
would be a reasonable alternative to the uniform prior for the 𝐵, but not for the other
infection response parameters. Note that another advantage of the Bayesian approach is
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the ability to incorporate prior knowledge about the parameters, if available, into the
model specification via informative prior distributions.
All models were fit using R version 2.15 interfaced with JAGS through the
R2JAGS package (R core team 2012, Plummer 2003).
3.3. ILLUSTRATIVE EXAMPLES
3.3.1. Lymphocyte response to equine arteritis virus infection in horses
Our first example references the case studies on equine arteritis virus (EAV) from
Chapter 1. In the experimental infection study by Go et al (2011), lymphocyte counts
were determined from blood samples collected at 0, 2, 4, 6, 8, 10, 12, 14, 21, 28, 35 and
42 days following challenge with a virulent, recombinant Bucyrus strain of EAV. In the
original study there was a total of eight mares belonging to two groups, one with the in
vitro susceptible CD3+ T cell phenotype and one with the resistant phenotype, and the
purpose was to compare the time course of lymphocyte counts (and other responses)
between the two groups. For the present example we ignore the group structure and
consider the eight mares as a single sample. Figure 3.2 presents the observed, subjectspecific febrile response profiles for the two groups.
All eight profiles suggest a single-peaked response with a common pre- and postinfection baseline lymphocyte count, although the baseline level varies considerably
among horses. Because the counts appear to be less variable during the response phase
than during baseline when the individuals are not infected, we applied a square root
transformation of the responses to stabilize the variance over the experimental period. We
modeled the transformed lymphocyte responses using the asymmetric normal-errors
NLHM in (3.3)-(3.6), with 𝑔 = 1. Satisfactory convergence was achieved with 75,000
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MCMC iterations following 25,000 burn-in. Convergence diagnostics and supplemental
plots are included in Appendix A. The posterior estimates are summarized in Table 3.1.

Figure 3.2 Observed lymphocyte response profiles for eight mares challenged with the
virulent, recombinant Bucyrus strain of EAV

Figure 3.3 Square root-transformed lymphocyte response profiles
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The population parameters characterize the mean lymphocyte response of mares
to inoculation with the Bucyrus strain of EAV. (More accurately, they represent the mean
infection response parameter values for the populations from which the sample was
drawn. If the samples were selected at random from a well-defined population then the
posterior means can be interpreted as estimates of the true mean values within the source
population.) On the transformed (square root) scale, the mean population baseline
lymphocyte level was estimated to be 1.6 𝐾/𝜇𝐿, with a posterior 95% credible interval
(1.5, 1.7). Thus, the probability is 95% that the true (transformed) population baseline
lymphocyte level is between 1.5 and 1.7 𝐾/𝜇𝐿 . The mean population time to peak
response was 8.3 days (7.6, 9.0), and the maximum decline in lymphocyte level was -0.8
𝐾/𝜇𝐿 (-1.0, -0.6). The mean population 𝐹𝑊𝐻𝑀 was 5.5 days (4.4, 6.8), and the large
difference in 𝐻𝑊𝐻𝑀𝑙 [4.1 (3.1, 5.1)] and 𝐻𝑊𝐻𝑀𝑟 [1.4 (1.2, 2.2)] indicates that the time
from onset to maximum lymphocyte decrease was nearly triple the time for the return
from peak to baseline lymphocyte level.
The variance component estimates quantify the extent to which individual
lymphocyte response parameters may vary about their corresponding population mean
values. Thus for example, for a particular mare from the source population inoculated
with the Bucyrus strain of EAV, it would be unusual to observe a maximum drop in
(square root-transformed) lymphocyte count of less than 𝐼 − 1.96𝜎𝐼 = −0.4 𝐾/𝜇𝐿 below
baseline count or more than 𝐼 + 1.96𝜎𝐼 = −1.2 𝐾/𝜇𝐿 below baseline. The population
mean response curve is presented in Figure 3.4.
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Table 3.1. Posterior estimates of population lymphocyte response parameters following
challenge of eight mares with the virulent, recombinant Bucyrus strain of EAV
Parameter
Mean 2.5% quantile 97.5% quantile
Population infection response parameters
1.6
1.5
1.7
𝐵
-0.8
-1.0
-0.6
𝐼
8.3
7.6
9.0
𝑝
5.5
4.4
6.8
𝐹𝑊𝐻𝑀
4.1
3.1
5.1
𝐻𝑊𝐻𝑀𝑙
1.4
1.2
2.2
𝐻𝑊𝐻𝑀𝑟
Variance components
0.22
0.12
0.42
𝜎𝐵
0.21
0.05
0.47
𝜎𝐼
0.32
0.01
0.96
𝜎𝑝
0.17
0.01
0.50
𝜎𝑙𝑜𝑔 𝑙
0.92
0.09
1.94
𝜎𝑙𝑜𝑔 𝑟
0.68
0.03
1.85
𝜎

Figure 3.4. Population lymphocyte response curve, with pointwise 95% posterior
credible intervals, for eight mares following experimental challenge with the virulent,
recombinant Bucyrus strain of EAV. Circles indicate observed lymphocyte counts.
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3.3.2. Febrile response to equine arteritis virus infection in horses
For our second example we revisit the comparison of population febrile responses
to the Bucyrus and Kentucky-84 strains of EAV. This example was discussed in Chapter
2 where we modeled the febrile responses using the symmetric normal-errors NLHM
(2.1)-(2.7). To review briefly, two separate experiments were conducted in which core
body temperature (CBT) was observed on days -7, -4 and -2 prior to inoculation and on
days 0, 2, 4, 6, 8, 10, 12 and 14 post-inoculation (DPI). In one of the experiments eight
mares were challenged with the Bucyrus strain of EAV whereas in the second eight
stallions were challenged with the KY-84 strain. Figure 3.5 presents the observed,
subject-specific febrile response profiles for the two groups.

Figure 3.5 Observed febrile response profiles for eight mares challenged with the
Bucyrus strain of EAV, and eight stallions challenged with the Kentucky-84 strain
All sixteen profiles suggest a single-peaked response with a common pre- and
post-infection baseline body temperature. We modeled the febrile responses using the
asymmetric

normal-errors

NLHM

in

(3.3)-(3.6),
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with 𝑔 ∈ {1,2}. Satisfactory

convergence was achieved with 100,000 MCMC iterations per three chains, including
25,000 burn-in. Convergence diagnostics and supplemental plots are included in
Appendix A. Posterior estimates are summarized in Table 3.2.
In many respects the febrile responses of the two groups were quite similar. The
estimates of baseline CBT for example, 𝐵(1) = 99.4℉ and 𝐵(2) = 99.3℉, are nearly
identical as might be expected. However they differed with respect to peak fever intensity
and time to peak fever. On average, in the stallions challenged with the KY-84 strain, the
febrile response peaked 𝑝(2) = 7.1 days after inoculation at an intensity of 𝐼 (2) = 4.7℉
above baseline CBT. The 95% posterior credible intervals (CI) for 𝑝(2) and 𝐼 (2) indicate
that the true population means for time-to-peak and peak intensity could plausibly lie in
the intervals (6.6, 7.4) and (4.1, 5.2), respectively. By comparison, in the mares
challenged with the Bucyrus strain, the febrile response peaked 𝑝(1) = 7.8 days (7.3, 8.4)
after inoculation at an intensity of 𝐼 (1) = 3.5℉ (2.7, 4.2) above baseline CBT.
Expressing the posterior means for the scale parameters 𝑙 (𝑔) and 𝑟 (𝑔) in terms of
𝐻𝑊𝐻𝑀 and 𝐹𝑊𝐻𝑀 increases their interpretability, so we report only those means in
Table 3.2. We see that there was little difference between the groups in the mean
duration of the febrile response, with 𝐹𝑊𝐻𝑀 (1) = 5.7 days (4.8, 7.2) and 𝐹𝑊𝐻𝑀 (2) =
5.6 days (4.8, 6.5). The response in both groups was strongly asymmetric as indicated by
(1)

the posterior means for 𝐻𝑊𝐻𝑀𝑙
(1)

posterior means for 𝐻𝑊𝐻𝑀𝑟

(2)

and 𝐻𝑊𝐻𝑀𝑙
(2)

being more than three times the

and 𝐻𝑊𝐻𝑀𝑟 . In other words, recovery from fever was

much more abrupt than onset.
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Table 3.2. Posterior estimates of population febrile response parameters following
challenge of eight mares with the Bucyrus strain of EAV and eight stallions with the KY84 strain of EAV
Bucyrus strain (mares)
2.5%
97.5%
Parameter Mean
quantile quantile
Population infection response parameters
99.4
99.0
99.8
𝐵(1)
(1)
3.5
2.7
4.2
𝐼
(1)
7.8
7.3
8.4
𝑝
(1)
5.7
4.8
7.2
𝐹𝑊𝐻𝑀
(1) 4.3
3.5
5.1
𝐻𝑊𝐻𝑀𝑙
(1) 1.4
1.2
2.5
𝐻𝑊𝐻𝑀𝑟
Variance components
(1)
0.46
0.17
0.97
𝜎𝐵
(1)
0.90
0.34
1.91
𝜎𝐼
(1)
0.23
0.01
0.74
𝜎𝑝
(1)
0.09
0.00
0.30
𝜎
𝑙𝑜𝑔 𝑙
(1)
𝜎𝑙𝑜𝑔 𝑟

0.81

0.04

3.07

𝜎

0.68

0.62

0.75

KY-84 strain (stallions)
2.5%
97.5%
Parameter Mean
quantile quantile
𝐵(2)
𝐼 (2)
𝑝(2)
𝐹𝑊𝐻𝑀 (2)
(2)
𝐻𝑊𝐻𝑀𝑙

99.3
4.7
7.1
5.6
4.3

98.9
4.1
6.6
4.8
3.5

99.6
5.2
7.4
6.5
5.1

𝐻𝑊𝐻𝑀𝑟

1.3

1.2

1.7

𝜎𝐵
(2)
𝜎𝐼
(2)
𝜎𝑝

0.44
0.55

0.15
0.06

0.94
1.33

0.27

0.01

0.74

𝜎𝑙𝑜𝑔 𝑙

(2)

0.18

0.03

0.43

𝜎𝑙𝑜𝑔 𝑟
𝜎

(2)

0.23

0.01

0.70

0.68

0.62

0.75

(2)

(2)

Interpretation of the variance component estimates is the same as in the onesample case. Thus for example, for a particular mare from the source population
inoculated with the Bucyrus strain of EAV, it would be quite unusual to observe a fever
(1)

that peaked at less than 𝐼 (1) − 1.96𝜎𝐼
(1)

𝐼 (1) + 1.96𝜎𝐼

= 1.7℉ above baseline CBT or at higher than

= 5.3℉ above baseline. The population response curves for the two

groups are presented in Figure 3.6.
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Figure 3.6. Population febrile response curves, with pointwise 95% posterior credible
intervals, for mares challenged with the Bucyrus strain of EAV, and stallions challenged
with the Kentucky-84 strain
We can contrast the population response parameters for the two groups simply by
monitoring the posterior distributions of their differences. These are presented in Table
3.3 for baseline, peak fever intensity, time to peak fever, and response duration as
indexed by 𝐹𝑊𝐻𝑀. We see that zero is excluded from the posterior 95% CI’s for the
differences in both peak intensity and time to peak. We conclude that the febrile
responses of the two groups differ with respect to these two characteristics.
Table 3.3. Posterior estimates of group differences in population parameters
Parameter
𝐵(2)− 𝐵(1)
𝐼 (2)− 𝐼 (1)
𝑝(2)− 𝑝(1)
𝐹𝑊𝐻𝑀 (2) − 𝐹𝑊𝐻𝑀 (1)

Mean
-0.11
1.2
-0.72
-0.14

Standard
deviation
0.28
0.48
0.34
0.83
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2.5%
quantile
-0.66
0.25
-1.4
-1.8

97.5%
quantile
0.44
2.2
-0.1
1.1

In comparing the asymmetric analysis in this section with the symmetric analysis
in Chapter 2 we note that the asymmetric model placed the time to peak estimates for
both groups about 1.5 days earlier than did the symmetric model.
3.4. ESTIMATION AND INFERENCE FOR ONSET AND RECOVERY TIMES
IN THE NORMAL-ERRORS NLHM
The normal-errors NLHM developed in Chapters 2 and 3 was specified in such a
way that its parameters would correspond to biologically meaningful properties of the
infection response. In the asymmetric model (3.3)-(3.6), the baseline response level is
represented by 𝐵, the peak response intensity by 𝐼, and the time to peak response by p.
The parameters 𝑟 and 𝑙 can be viewed as indices of, respectively, the duration of the onset
and recovery phases of the response. Although adequate for testing hypotheses about
differences in the duration of onset or recovery, or the total response duration, among
treatment groups, these scale parameters lack satisfying descriptive interpretations.
Quantities derivable from 𝑟 and 𝑙, such as HWHM and FWHM, can partially address the
need for more intuitive measures of response duration. However for investigators
interested in questions such as, “On average, how many days (or hours) after inoculation
does the response onset (or recovery) occur?” or “Does treatment alter the timing of
response onset (or recovery)?” none of these measures is adequate. In this section we
propose a method of estimating the timing of response onset and recovery for the normalerrors NLHM.
3.4.1. Method
The model (3.3)-(3.6) is appropriate for response variables which vary in a
consistent manner about some mean level prior to challenge, during infection, and
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following recovery. This follows from the distributional assumption about the response
variable specified in (3.3). Observe that for an individual in its baseline, uninfected state,
the response distribution specified in (3.3) and (3.4) simplifies to
𝑦𝑖𝑗 |𝐵𝑖 ~𝑁(𝐵𝑖 , 𝜎 2 )

(3.9)

Thus, in the baseline state 95% of an individual’s observed responses will fall
within the interval [𝐵𝑖 − 1.96𝜎, 𝐵𝑖 + 1.96𝜎]. Intuitively, a series of observations falling
outside that interval in the same direction (either all above or all below) would be a
strong indication that onset had occurred for that particular individual.
Now consider selecting an uninfected individual at random from the source
population and sampling the response variable. Without knowing that particular
individual’s true baseline level, a reasonable expectation for the observed value would be
the population baseline 𝐵. But the specific value we observe is influenced both by the
inherent variability in the individual’s responses and the amount by which the
individual’s baseline differs from the population baseline 𝐵. In the model these quantities
are represented by 𝜎 2 and 𝜎𝐵2 . Thus, marginally over the entire population, we have
𝑦𝑖𝑗 ~𝑁(𝐵, 𝜎𝐵2 + 𝜎 2 )

(3.10)

It follows that approximately 95% of all observations made under baseline (i.e.
uninfected) conditions will fall within the interval
[𝐵 − 1.96√𝜎 2 + 𝜎𝐵2 , 𝐵 + 1.96√𝜎 2 + 𝜎𝐵2 ].

(3.11)

We can think of this interval as representing bounds on normal variability of the
response variable among uninfected individuals in the sources population. When model
(3.3)-(3.6) is fitted to data from an EI study we obtain an estimate of the population
average response to infection. We define population average onset time as the earliest
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time point at which the population average response (𝑂) departs from this interval of
normal variability. Similarly, we define the population average recovery time (𝑅) as the
earliest time at which the population average response returns to the interval of normal
variability. Finally, we define population average response duration as the time between
onset and recovery, i.e. 𝐷 = 𝑅 − 𝑂.
3.4.2. Procedure
In the Bayesian setting implementation is trivial. After the final model is fit,
posterior distributions for 𝑂 , 𝑅 and 𝐷 can be obtained as follows. For each MCMC
iteration:
1. Reconstruct the population mean response curve from the parameter 𝜷(𝑚)
obtained for that iteration. [Note that the (𝑚) superscript in this context refers to
the sampled value obtained at MCMC iteration 𝑚, and is not to be confused with
the (𝑔) superscript notation used in (3.5) and (3.6) to denote group membership.]
(𝑚)

2. Extract the parameter values B (𝑚), σ(𝑚) and 𝜎𝐵 obtained at that iteration.
3. Determine the earliest time at which the population mean response curve for
iteration 𝑚 escapes the interval (3.11). This is the estimated population average
onset time for iteration 𝑚, denoted O(𝑚) ;
4. Determine the earliest time at which the population mean response curve for
iteration 𝑚 returns to the interval (3.11). This is the estimated population average
recovery time for iteration 𝑚, denoted R(𝑚);
5. Define the estimated population average response duration for iteration 𝑚 as
D(𝑚) = R(𝑚) − O(𝑚) .
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Collect the MCMC estimates O(𝑚) , R(𝑚) and 𝐷 (𝑚) into vectors 𝑶 , 𝑹 and 𝑫 .
These vectors represent samples from the posterior distributions of 𝑂 , 𝑅 and 𝐷 from
which posterior means and credible intervals may be extracted.
3.4.3. Illustrative example: Lymphocyte count
Figure 3.7 presents population mean onset and recovery times of the lymphocyte
response for mares challenged with the recombinant Bucyrus strain of EAV. The vertical
blue line at 4.7 DPI on the x-axis indicates that the decline in lymphocyte count was first
detectable, on average, at 4.7 days post-challenge. The lighter blue rectangular region
surrounding this line indicates the posterior 95% credible interval (3.3, 6.9). Similarly,
the vertical blue line at 9.4 DPI on the x-axis indicates that return to baseline lymphocyte
count occurred, on average, 9.4 days post-challenge. The light blue region surrounding
this line indicates the posterior 95% credible interval for recovery (8.5, 10.7). The total
duration of the lymphocyte response – the time from initial onset to recovery to baseline
level – was estimated to be 4.7 days (1.8, 6.8).

Figure 3.7. Estimated population mean onset and recovery times for lymphocyte
response for mares challenged with the recombinant Bucyrus strain of EAV
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3.4.4. Illustrative example: Febrile response
Figure 3.8 presents population mean onset and recovery times of the febrile
response to EAV infection for mares challenged with the recombinant Bucyrus strain of
EAV and stallions challenged with the KY-84 strain. The vertical blue line at 3.4 DPI on
the x-axis indicates that in the Bucyrus group the onset of fever occurred at 3.4 days postchallenge. The lighter blue rectangular region surrounding this line indicates the posterior
95% credible interval (2.2, 4.9). Similarly, the vertical blue line at 9.1 DPI on the x-axis
indicates that return to baseline body temperature in the Bucyrus group occurred, on
average, 9.1 days post-challenge. The light blue region surrounding this line indicates the
posterior 95% credible interval for recovery (8.5, 10.6).

Figure 3.8. Estimated population mean onset and recovery times for febrile response to
EAV infection. Bucyrus strain (mares)
Onset and recovery estimates and accompanying credible intervals for the KY-84
group are indicated by the orange lines and rectangular regions. Estimated onset for that
group was considerably earlier at 1.8 days (0.6, 3.1) and recovery was also slightly earlier
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at 8.7 days (8.2, 9.2). However as suggested by the overlapping credible intervals
(illustrated by the brownish regions in Figure 3.8), neither of these differences was
judged to be statistically significant. The estimated group difference in duration of the
febrile response [Bucyrus 5.8 days (3.7, 7.7) and KY-84 6.8 (5.3, 8.2)] was likewise not
significant. Note that the mean duration estimate for the KY-84 group is 21% higher than
the estimate of mean FWHM from Table 3.2, but the estimate for the Bucyrus group is
less than 2% greater.
3.5. DISCUSSION
Our primary aim in this chapter was to extend the normal-errors NLHM model to
accommodate asymmetric responses. To accomplish this we proposed a mean response
function consisting of two half-Gaussian curves constrained to meet at a common peak.
There are several other examples in that statistical literature of piecewise models for
peaked, asymmetric longitudinal responses. Huisman et al (1993) proposed a set of five
response functions for modeling temporal variations in the abundance of vegetation
species in response to environmental changes. The models are based on logistic equations
of the form (1 + 𝑒 𝑎+𝑏𝑥 )−1 . Two of the curves are analogous to our symmetric and
asymmetric Gaussian-based response models. Mü ller and Rosner (1997) introduced a
model for analyzing the hematologic (white blood cell) response of patients to
chemotherapeutic medications. They used a piecewise linear and logistic response
function consisting of a linear baseline component, a logistic “recovery” component, and
a second linear “onset” component connecting the baseline and recovery portions of the
curve. Gö ssl et al (2001) proposed a model for the hemodynamic response function
(HRF) which arises in functional magnetic resonance imaging (fMRI). Neuronal

75

activation in the brain in response to an experimental stimulus results in local increases in
blood flow and oxygen level. These changes follow a well-defined pattern known as the
hemodynamic response. The HRF of G ö ssl and colleagues is a piecewise function
consisting of two linear and three truncated Gaussian components for a total of five
regions (baseline, increase, plateau, decrease and undershoot).
We implemented our infection response model as a Bayesian hierarchical
nonlinear model. The primary reason for this decision was the inability of frequentist
methods to achieve convergence when using the piecewise response function (3.4). Jang
et al (2013) reported successfully fitting several piecewise mixed effects models of
cardiac function using frequentist methods, specifically the nlme package in R. However
their data set included 80 observations per individual. This suggests that our difficulties
may have been due to the relatively sparsity of our data at the individual level. A second
reason for preferring the Bayesian approach is that maximum likelihood estimation and
inference for NHLM’s are based on asymptotic results that may not hold for the relatively
small numbers of subjects typical of EI studies. The hematologic and hemodynamic
response models mentioned above were both implemented as Bayesian hierarchical
nonlinear models.
3.5.1. Illustrative examples
The illustrative examples highlight some concerns that can only be addressed by the
investigator at the time of study design. Intensity of measurement occasions at the
individual level appears to be a critical factor in the feasibility of applying piecewise
NLHM’s to longitudinal EI data. Based on both the illustrative examples and the
simulation results from Chapter 2, we can make some recommendations. In general, we
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advise sampling as intensively as practically possible over the duration of the response.
However there are certain periods during which sampling intensity is particularly
relevant. First, we advise taking several baseline measurements both pre-challenge and
post-recovery in order to better locate the individual baseline response levels. Second, we
advise sampling intensively during periods when the response variable is expected to
change rapidly, which for a single-peaked response means during the onset and recovery
phases. In the febrile response example, core body temperature for all horses dropped
rapidly after peaking. In many cases rapid onset will occur within the first two or three
days post-inoculation, particularly with quantities like viral load as we will discuss in
Chapter 4, so intensively sampling is advisable during this period.
The febrile response example illustrates yet another attractive feature of a
Bayesian implementation. Recall that in Chapter 2 the symmetric NLHM was
implemented as a frequentist nonlinear mixed effects model. It is well known that
variance components tend to be underestimated by maximum likelihood (ML) methods
for both linear and nonlinear mixed models, because they do not take into account the
loss in degrees of freedom incurred in estimating the fixed effects.

To enable a

comparison of variance component estimates for the ML and Bayesian approaches, we
reanalyzed the febrile response data from Section 3.3.2 using the symmetric NLHM from
Chapter 2, but implemented as a Bayesian NLHM. We found that the posterior means for
𝜎𝐵 , 𝜎𝐼 and 𝜎𝑝 were between 12% and 26% higher than the ML estimates from Chapter 2.
Restricted maximum likelihood (REML) estimation often produces more accurate
variance component estimates than ML (Harville 1977). However in this particular
example, the REML and ML estimates were nearly identical.
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3.5.2. Estimation and inference for response onset and recovery
There are some examples in the literature of methods used to identify onset and
recovery times in longitudinal responses. Fox (2008) used RM-ANOVA to estimate the
time at which postural control (essentially, balance) returned to baseline level after
exercise. They found that “the effects of fatigue persisted for up to 13 minutes before
postural control returned to baseline.” As a result it was recommended that clinicians
responsible for assessing athletes for concussions during play or practice should wait at
least 13 minutes so that effects due to fatigue are not mistakenly interpreted as a sign of
concussion.
Piecewise models such as those discussed above contain built-in change point
parameters that can be used to estimate the timing of key transitions in the response
trajectory. For example the hematologic response model by M𝐮̈ ller and Rosner includes a
parameter that marks the transition point from the baseline phase, modeled as a horizontal
line, to the onset phase, which is modeled as a separate line connecting the baseline
segment to the recovery segment.
Our approach aims to identify the population average time at which a clinically
meaningful change in the response variable from the baseline, uninfected state is
detectable. This is different from the time at which the underlying immune response to
infection commences. We note also that in the frequentist setting, it would be possible to
apply the same approach to estimating population mean onset, recovery and duration via
the bootstrap (Efron 1979, Das 1999).
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CHAPTER FOUR
A Bayesian nonlinear hierarchical model for viral load
4.1. INTRODUCTION
In Chapter 3, we presented a Bayesian normal-errors NLHM for asymmetric
infection responses. Frequently in MC experiments involving viral pathogens, a primary
focus is the time course of the viral load in blood, feces or other fluids or excreta. For the
individuals in such experiments, viral load will be exactly zero at all observation times
prior to inoculation and after clearance of the virus. During infection, however, viral load
can be viewed as fluctuating randomly about some systematic trajectory (Figure 4.1).
Because viral loads are nonnegative, the assumption of identical, normally
distributed errors is clearly untenable. We propose an NLHM in which the viral load at
each time point is modeled as a Poisson random variable with mean given by a compact
kernel function such as the Tricube or Epanechnikov. Because the variance of a Poisson
random variable is equal to its mean, when the mean viral load is equal to zero (i.e. preonset or post-recovery) the variance will be also. Similarly, when the mean viral load is
positive (i.e. during infection) the variance will be positive, and the variance will increase
with the mean.
In this Chapter we propose a NLHM suitable for modeling viral load and other
response variables that do not vary when the subject is not infected. We provide two
illustrative examples in which the proposed model is applied to viral load data from
actual experimental infection studies.
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Figure 4.1. A typical nasal viral load response profile for a human subject
experimentally infected with rhinovirus (Mallia 2012)
4.2. BAYESIAN NONLINEAR HIERARCHICAL MODEL FOR VIRAL LOAD
We model the individual response profiles with piecewise half-kernel functions,
where K in (16) is any nonnegative, compact kernel function. The normalizing constant is
replaced with an intensity parameter 𝐼𝑖 which is specific to each individual and
corresponds to mean peak intensity. Because viral load has a natural baseline value of
zero, subject-specific baseline parameters, as in (8), are not required.
Level 1 (model of intra-individual variability)
𝑦𝑖𝑡 ~𝑃𝑜𝑖𝑠(𝜇𝑖𝑡 )

(4.1)

𝜇𝑖𝑡 = 𝐾 ∗ (𝑡, 𝑝𝑖 , 𝑙𝑖 , 𝑟𝑖 )

(4.2)

0
𝐾 ∗ (𝑡 ) =

𝐼𝑖 × 𝐾 (
𝐼𝑖 × 𝐾 (
{0

if 𝑡 ≤ 𝑝𝑖 − 𝑙𝑖
𝑡−𝑝𝑖
𝑙𝑖
𝑡−𝑝𝑖
𝑟𝑖

) if 𝑝𝑖 − 𝑙𝑖 < 𝑡 ≤ 𝑝𝑖
) if 𝑝𝑖 < 𝑡 < 𝑝𝑖 + 𝑟𝑖
if 𝑡 ≥ 𝑝𝑖 + 𝑟𝑖
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(4.3)

An attractive consequence of using a compact kernel 𝐾 in the specification of the
mean infection response function 𝐾 ∗ is that we obtain estimates of response onset time
for individual i as 𝑝𝑖 − 𝑙𝑖 , recovery time as 𝑝𝑖 + 𝑟𝑖 , and response duration as 𝑑𝑖 = 𝑝𝑖 +
𝑟𝑖 − (𝑝𝑖 − 𝑙𝑖 ) = 𝑙𝑖 + 𝑟𝑖 .
Level 2 (model of inter-individual variability)
Collect the response parameters for individual 𝑖, into a vector
𝜷𝑖 = [𝐼𝑖 , 𝑝𝑖 , 𝑙𝑖 , 𝑟𝑖 ]𝑇 .

(4.4)

Level 2 (model of inter-individual variability)
𝜷𝑖 = 𝜷(𝑔) + 𝒃𝑖

(4.5)

𝒃𝑖 ~𝑁(0, 𝑫(𝑔) ), where 𝑫(𝑔) = diag (𝜎𝐼2(𝑔) , 𝜎𝑝2(𝑔) , 𝜎𝑙2(𝑔) , 𝜎𝑟2(𝑔) )

(4.6)

Level 3 (hyperprior distribution)
Prior distributions on 𝜷, 𝑫, and 𝜎 were the same as for the normal-errors model in
Chapter, with one exception. Because the response onset cannot occur prior time zero, we
have 𝑝 − 𝑙 ≥ 0 ⇒ 𝑙 < 𝑝. Thus we can specify 𝑙~𝑈𝑛𝑖𝑓(0, 𝑝).
As previously, the following definitions are implicit in (4.1)-(4.6).
𝜷𝑖 = [𝐼𝑖 , 𝑝𝑖 , 𝑙𝑖 , 𝑟𝑖 ]𝑇 .

(4.7)
𝑇

𝜷(𝑔) = [𝐼 (𝑔) , 𝑝(𝑔) , 𝑙 (𝑔) , 𝑟 (𝑔) ] , 𝑔 ∈ {1,2}

(4.8)

4.3. ILLUSTRATIVE EXAMPLES
4.3.1. Effect of body condition on viral shedding in migratory birds
This example refers to the case study from Chapter 1 on influenza A viral
shedding in ducks. Recall that the original experiment included four treatment groups.
For the sake of simplicity we focus here on a comparison of the viral shedding pattern of
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the wild lean group to that of the wild normal group. Viral shedding profiles are
presented in Figure 4.2. Peak shedding for birds in the wild normal group generally was
higher than in wild lean birds, although there were exceptions. Mean duration of
shedding also appears to be longer in the wild normal group.

Figure 4.2. Observed viral shedding profiles for nine wild-caught ducks with normal
body condition and nine wild-caught ducks with lean body condition following
experimental challenge with AIV (observations for days 11 through 28 not shown)
We modeled the viral shedding data using the Poisson NLHM in (4.1)-(4.6) with
𝑔 ∈ {1,2}. Based on the observed profiles in Figure 4.2 we selected a piecewise Tricube
kernel function as the model for the mean response functions. Thus the function 𝐾 in
(4.3) is given by
𝐾(𝑢) = (1 − |𝑢|3 )3 .

(4.9)

Satisfactory convergence was achieved with 175,000 MCMC iterations following
25,000 burn-in, for all except the recovery parameters in the wild lean group, i.e. 𝑟 (2) and
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(2)

𝜎𝑟 . We discuss possible causes in §4.5. Convergence diagnostics and supplemental
plots are included in Appendix A. Posterior estimates are reported in Table 4.1.
Table 4.1. Posterior estimates of population viral shedding parameters for wild normal
and wild lean groups experimentally challenged with AIV
Wild-caught normal
Wild-caught lean
2.5%
97.5%
2.5%
97.5%
Parameter
Mean quantile quantile Parameter
Mean quantile quantile
Population infection response parameters
470
355
584 𝐼 (2)
331
197
468
𝐼 (1)
(1)
(2)
1.9
1.3
2.5
2.5
1.4
3.7
𝑝
𝑝
1.3
0.4
2.0 𝑙 (2)
1.5
0.2
2.8
𝑙 (1)
(1)
(2)
4.4
3.4
5.0 𝑟
3.4
1.3
4.9
𝑟
Variance components
(1)
166
98
291 𝜎 (2)
189
110
341
𝜎
𝐼
(1)
𝜎𝑝
(1)
𝜎𝑙
(1)
𝜎𝑟

𝐼

1.8

1.0

3.2

0.8

1.6 𝜎𝑝(2)
1.9 𝜎 (2)

2.7

1.6

4.5

1.7

2.0

3.1

1.8

4.8

0.93

0.55

1.3
1.9

𝑙
(2)
𝜎𝑟

Figure 4.3 illustrates the population average time courses for influenza viral
shedding in the wild normal and wild lean groups. The estimated time to peak was earlier
in the wild normal group (1.9 days to 2.5 days) and the mean peak shedding intensity was
139 units [𝑙𝑜𝑔10 (𝐺𝐸𝐶 )/140 𝜇𝑙] greater.
Table 4.2 summarizes the posterior distributions for the group differences in the
population infection response parameters. The posterior interval (-314, 38) for
𝐼 (2) − 𝐼 (1) includes zero, implying that peak viral shedding intensity was significantly
greater in the captive normal group. The interval for 𝑝(2) − 𝑝(1) includes zero, implying
no difference in mean time to peak shedding.
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Table 4.2. Posterior estimates of differences in population viral shedding
parameters for wild normal and wild lean groups challenged with AIV
95% posterior credible interval
Parameter
𝐼 (2) − 𝐼 (1)
𝑝(2) − 𝑝(1)
(1)

Mean

2.5% quantile
-139
0.6

97.5% quantile
-314
-0.7

38
1.9

denotes normal body condition and (2) denotes lean body condition

Figure 4.3. Estimated population viral shedding curves, with pointwise 95% posterior
credible intervals, for wild normal and wild lean groups challenged with AIV
4.3.2. Effects of rhinovirus infection in chronic obstructive pulmonary disease
Our second example refers to the case study from Chapter 1 on the effect of
rhinovirus infection on persons with chronic obstructive pulmonary disease (COPD). To
review briefly, Mallia and colleagues (2006, 2011, 2012, 2013) recently developed a
human rhinovirus (HRV) challenge model for COPD. In their 2011 study, thirteen
volunteers with COPD and thirteen controls with a similar smoking history, but normal
lung function, were recruited. All participants tested negative for serum neutralizing
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antibodies to rhinovirus 16 (RV-16). They were inoculated with a 10 TCID50 dose of RV16 and followed for six weeks post-infection. Viral loads in nasal lavage and sputum,
lung function, inflammatory markers, and upper and lower respiratory symptom scores
were sampled at varying intervals and intensities. Twenty-three subjects displayed
virological evidence of rhinovirus infection: eleven from the COPD group and twelve
from the control group. Data from those 23 subjects were analyzed to assess whether
experimental RV-16 infection induces exacerbation in persons with COPD.

Figure 4.4. Observed profiles of viral load in nasal lavage for eleven subjects with COPD
and twelve health controls following experimental challenge with RV-16
Our interest in this example is in the viral load in nasal lavage (VLN). Figure 4.4
presents the observed viral loads in nasal lavage (VLN) following inoculation over the
course of six weeks, for all subjects in each group. In each group the viral load increases
to a peak very rapidly for most subjects and decreases back to zero more gradually, as the
host immune response neutralizes and eliminates the virus. The figure suggests that the
mean time to complete viral clearance may be greater in the control group, although this
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impression is based largely on just two control subjects with clearance times greater than
thirty days.
As in the previous example we modeled the rhinovirus data using the Poisson
model in (4.1)-(4.6) with 𝑔 ∈ {1,2} . Again we selected a piecewise Tricube kernel
function (4.9) as the model for the mean response functions, although other kernel
functions could be used. Satisfactory convergence of the Markov chains was achieved
with 200,000 MCMC iterations (50,000 burn-in) for all except for the onset parameters in
(1)

both groups, i.e. 𝑙 (1) , 𝑙 (2) , 𝜎𝑙

(2)

and 𝜎𝑙 . We discuss the cause of these exceptions in

§4.5. Convergence diagnostics and supplemental plots are included in Appendix A.
Table 4.3. Posterior estimates of population viral load response parameters for controls
and subjects with COPD
Controls
2.5%
97.5%
Parameter Mean
quantile quantile
Population infection response parameters
550
456
644
𝐼 (1)
(1)
3.3
1.6
4.9
𝑝
(1)
0.75
0.06
1.5
𝑙
(1)
17.4
14.6
20.2
𝑟
Variance components
(1)
148
92
248
𝜎
𝐼
(1)
𝜎𝑝
(1)
𝜎𝑙
(1)
𝜎𝑟

2.7

1.7

1.2

0.5

4.95

4.82

Parameter

COPD
2.5%
Mean
quantile

97.5%
quantile

𝐼 (2)
𝑝(2)
𝑙 (2)
𝑟 (2)

610
2.8
1.3
15.8

442
0.83
0.15
12.8

778
5.0
2.6
18.8

𝜎𝐼
4.3 𝜎𝑝(2)
2.2 𝜎 (2)

(2)

248

151

416

4.0

1.9

8.1

2.2

1.4

3.7

5.0

4.8

4.5

5.0

𝑙
(2)
𝜎𝑟

Posterior estimates are reported in Table 4.3. Figure 4.5 illustrates the populationaveraged time courses for RV-16 viral load in nasal lavage in the COPD and control
groups. Peak viral load was reached earlier in COPD subjects, at 2.8 days (0.8, 5.0)
compared to 3.3 days (1.6, 4.9) in controls. Peak intensity was estimated at 610 units
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(442, 778) in the COPD group compared to 550 units (456, 644) in controls. Thus, the
average response in the COPD group began earlier and peaked earlier at a higher level
than the average response in the control group.

Figure 4.5. Estimated population time course for viral load in nasal lavage, following
RV-16 challenge with pointwise 95% posterior credible intervals
Table 4.4 summarizes the posterior distributions for the group differences in peak
intensity and time to peak. We see that both posterior 95% credible intervals include the
null value of zero, suggesting that the differences described above are indistinguishable
from random noise. Thus, although the original analysis detected a difference in viral
loads between COPD subjects and controls at 6 DPI, our analysis found no significant
difference in the population average response curves. This is noteworthy because it is
unclear why one would expect COPD to influence the time course of viral load, and a
false positive finding can be a distraction.
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Table 4.4. Posterior estimates of differences in population viral load
response parameters for controls and subjects with COPD
Parameter
𝐼 (2) − 𝐼 (1)
𝑝(2) − 𝑝(1)
(1)

Mean
60.0
-0.5

95% posterior credible interval
2.5% quantile 97.5% quantile
-130.9
251.4
-3.0
2.2

denotes the control group and (2) denotes the COPD group

4.4. ONSET AND RECOVERY TIMES IN THE VIRAL LOAD NLHM
In Chapter 3, we introduced a method for estimating onset and recovery times for
the normal-errors NHLM. The approach was based on identifying limits on the plausible
values for the mean response when all the individuals in a sample are in the baseline, or
nonresponsive, state. For the viral load NHLM (4.1)-(4.6) the solution to this problem is
trivial: natural candidates for onset and recovery time can be obtained as direct functions
of the model parameters. A glance at equation (4.3) shows that the transition from zero to
positive viral load occurs at time 𝑝𝑖 − 𝑙𝑖 , and the return from positive to zero viral load
occurs at time 𝑝𝑖 + 𝑟𝑖 . We define these times, respectively, as the population mean onset
and recovery times, and we estimate them with posterior means and credible intervals.
Figure 4.6 presents population mean onset and recovery times for the captive
normal group from the viral shedding example in §4.3.1. The vertical blue line at 0.59
DPI on the x-axis indicates that in the wild normal treatment group the onset of fever
occurred at 0.59 days (or about 14 hours) post-challenge. The light blue shaded region
surrounding this line indicates the posterior 95% credible interval (0.03 1.5). Similarly,
the vertical blue line at 6.3 DPI on the x-axis indicates that viral shedding in the captive
normal group ceased, on average, 6.3 days post-challenge. The posterior 95% credible
interval for recovery is (5.1, 7.1).
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Figure 4.6. Estimated onset and recovery times, with posterior 95% credible intervals,
for wild normal ducks challenged with AIV
Figure 4.7 illustrates onset and recovery for the wild-caught, lean treatment group.
Estimated onset for the wild lean group was later at 0.96 days (0.04, 2.64), or about 23
hours, and the point estimate for recovery was slightly earlier at 5.9 days (3.4. 7.9).
However the posterior credible intervals indicate that there is a great deal of uncertainty
in these point estimates. Figures A.17 and A.18 are panel plots of the individual,
observed viral shedding profiles. In both groups, there are very few observations within
the time intervals where onset and recovery occur, but the problem is particularly evident
in the wild lean group (Figure A.18). This likely explains the extreme lack of precision in
the onset and recovery estimates for that group. As a result, although the point estimates
of recovery time and response duration differ noticeably between the two groups, we
cannot declare the differences to be significant. However, more intensive sampling
during the onset and recovery phases may greatly increase precision. It is instructive to
compare Figures A.18 and A.11 – the latter being a panel plot of the observed core body
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temperature profiles for stallions challenged with the KY-84 strain of EAV from Chapter
3 – and the corresponding onset and recovery plots 4.7 and 3.7. The highly precise
posterior credible interval for recovery in the KY-84 group in Figure 3.7 is due to the
combination of (a) the similarity of the individual recovery trajectories in that group, and
(b) the presence of adequate numbers of observations sampled during the recovery phase.

Figure 4.7. Estimated onset and recovery times, with posterior 95% credible intervals,
for wild lean ducks challenged with AIV
4.5. DISCUSSION
For several reasons the normal-errors NLHM from Chapters 2 and 3 is not
appropriate for modeling viral load in EI studies. Viral load does not vary in uninfected
individuals prior to challenge nor after clearance, so that the constant variance
assumption is clearly violated. Furthermore, viral load must be positive, so it makes no
sense to model a subject’s viral load at each time point as a normal random variable.
Finally, during infection it may happen the variability in viral load increases as the mean
viral load increases. We have proposed a NLHM which better reflects viral load
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dynamics in EI studies. Although we modeled the individual responses as Poisson
random variables, there are other distributions that we might have chosen to address these
shortcomings of the normal-errors NLHM.
Our model is not mechanistic, in the sense that the choice of response function is
not informed by biological knowledge of viral kinetics. There are at least two other
domains in which researchers have developed both mechanistic and empirical NLHM’s
for studying the time course of viral load dynamics. A discussion of those cases will
provide a helpful context within which to interpret our findings.
In AIDS research, early efforts to model HIV dynamics in vivo date to the mid1990’s. It was known that infected individuals treated with reverse transcriptase or
protease inhibitors experienced an exponential decline of virus in plasma and a
simultaneous increase in CD4 cell counts (Herz et al 1996). Compartmental models,
very much like the susceptible-infected-recovered (SIR) models used in the study of
infectious disease transmission in epidemics, were developed to model the observed viral
dynamics (Perelson et al 1996, Ho et al 1995, Wei et al 1995). These models were based
on differential equations that describe the interactions among cells susceptible to
infection, infected cells and free virus (Huang et al. 2006). They have been instrumental
in understanding HIV pathogenesis and developing treatment strategies.
Wu et al (1998) extended the work of Perelson et al. by placing it in the
framework of the normal-errors NLHM. Fitgerald et al. (2002) proposed a normal-errors
NLHM of the HIV “rebound effect,” an increase in viral load which occurs in some
patients following the initial decrease caused by initiation of antiretroviral therapy. Both
of these were implemented in the nonlinear mixed model (NLMM) framework. Several
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authors have reported on the application of Bayesian methods to the modeling of HIV
dynamics including Frost et al. (2001), Han et al. (2002), Wolf et al. (2002), Wu (2005),
Huang et al. (2006). A recent paper by Huang (2013) describes a model more similar to
our own, namely, a piecewise Bayesian NLHM of viral load changes for HIV. The model
includes parameters that identify transition points in the HIV trajectory, such as the
previously mentioned rebound effect. Unlike the other HIV models we have described, it
is empirical rather than mechanistic. Its purpose (like that of our infection response
models) is to describe and estimate macro-level features of the response trajectories.
Efforts have also been made to apply NLHM to hepatitis viral kinetics. Neumann
et al. (1998) proposed a mechanistic model of hepatitis C virus (HCV) dynamics in
response to interferon-𝛼 therapy. O’Sullivan et al. (2008) developed a normal-errors
NLHM based on a logistic response function to empirically quantify long-term withinand between-subjects HCV variation untreated, chronically infected individuals. Snoeck
et al. (2010) introduced a mechanistic, normal-errors NLHM capable of flexibly
modeling a range of HCV responses to treatment with peginterferon 𝛼-2a±ribivarin.
4.5.1. Illustrative examples
In both the HIV and the hepatitis C models discuss above, the focus is on the
effect of therapeutic interventions on viral load in chronically infected individuals. The
normal-errors assumption is reasonable in those cases because subjects have established a
nonzero baseline level around which viral load fluctuates over time. In EI studies, the
interest centers on the response to acute infection in individuals not infected at the
beginning of the experiment. Thus normal-error models are not appropriate.
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In both of the illustrative examples we noted a lack of convergence in the MCMC
chains for certain of the onset and recovery parameters – both the population effects and
their variance components. In particular, this was observed for the recovery parameters
for the wild lean group in the influenza example, and the onset parameters in both the
COPD and control groups in the RV-16 example. This problem was not encountered in
the lymphocyte and febrile response examples in Chapter 3. These difficulties are
symptomatic of two fundamental issues that can be addressed through improved study
design. First, the response variable may have been sampled with insufficient intensity
during the onset and recovery phases. Second, the individual responses within a particular
group may be too dissimilar to permit them to be summarized by a single population
response curve. The lesson is that, in addition to the number of individuals per group, the
investigator should give careful thought to the sampling schedule and to the degree of
heterogeneity permitted among the individuals in each group. For example, if there are
significant differences in the way that male and females, or younger and older
individuals, respond to a particular infection, then consideration should be given to
restricting the samples accordingly, in order to reduce noise and increase power.
Wu et al (1998), Wu and Ding (2000) and Wu (2005) address the critical
importance of the sampling schedule in viral load studies. Although their focus is studies
of HIV dynamics, their comments are equally relevant to EI studies. For example Wu
(1998) suggests “sampling as frequently as possible during the first 8 hours until one
captures the drug effect time (the time that viral load starts to drop).” Obviously in EI
studies viral load will increase following inoculation rather than dropping following
treatment (as in HIV studies), but the message is the same: frequent sampling during the
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incubation period is important for modeling the true onset trajectory accurately.
Typically, however, in EI studies viral load is sampled at most daily during the first few
days, and less frequently thereafter. A study by Harris and McGwaltney (1996) clearly
demonstrates the rapid onset of rhinovirus infection. In eleven volunteers challenged with
rhinovirus type 39, mean time of symptom onset occurred was less than 2 hours and the
mean time to first detectable viral shedding was 11.3 hours. In this particular scenario it
would seem advisable to sample viral load at least every three or four hours over the first
day post-inoculation. Wu and colleagues suggest the use of Monte Carlo simulation as an
aid to determining an adequate sampling schedule.
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CHAPTER FIVE
Summary and future directions
5.1. Nonlinear hierarchical models for longitudinal EI studies
Longitudinal infection response data arise in many experimental infection studies
including those designed to demonstrate vaccine efficacy, explore disease etiology,
pathogenesis and transmission, or understand the host immune response to infection.
Very often such data are analyzed with inefficient and arguably inappropriate statistical
methods, frequently RM-ANOVA. This is not unique to EI studies; it has been noted by
researchers in many fields (Jang 2013, Matthews 1990). Major advances in methods for
analyzing longitudinal data that have occurred over the past fifty years, but investigators
in some disciplines – including those that utilize EI studies – continue to rely almost
exclusively on familiar, classical approaches. In some cases, such as EI where infection
responses are inherently nonlinear, newer methods may offer substantial gains in
accuracy and precision of parameter estimation and power. Our aim was to propose an
alternative approach to the analysis of longitudinal data from EI studies that incorporates
recent developments in the areas of nonlinear hierarchical models and Bayesian statistics.
In Chapter 2 we introduced a basic, single-peaked model for a symmetric
infection response which was based on the normal-errors NLHM with a Gaussian mean
response function. The parameters of that model correspond directly to biologically
meaningful properties of the infection response, including baseline, peak intensity, time
to peak and spread. In Monte Carlo simulation studies the NLHM outperformed RMANOVA across a broad range of scenarios, and under certain conditions the
improvement was substantial. Estimation in the NLHM was more precise than RM-
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ANOVA for all model parameters, and less biased for peak intensity and duration
parameters. We demonstrated the effects of the sampling schedule, interindividual
response variability and misspecification of the mean response function on estimation
and inference. Finally we illustrated the application of the symmetric NLHM to real data
as a frequentist nonlinear mixed model.
In Chapter 3 we extended the basic, symmetric response model from Chapter 1 by
incorporating a piecewise, half-Gaussian response function. Piecewise longitudinal
response models have been applied successfully in several fields including ecology
(Huisman et al 1993), cancer research (Mü ller and Rosner 1997), HIV/AIDS research
(Huang 2012) and functional magnetic resonance imaging (Gö ssl et al 2001). We chose
to implement the model as a Bayesian hierarchical nonlinear model to overcome
convergence problems and avoid reliance on asymptotic results associated with the
frequentist framework. The latter concern is relevant given the generally small-tomoderate sample sizes associated with EI studies. Through illustrative examples we
demonstrated the application to the description of lymphocyte decline following
experimental challenge with EAV and the comparison of febrile responses to challenge
with different strains of EAV. Finally we proposed a method for estimating infection
response onset and recovery times from the fitted model.
In Chapter 4 we considered modeling of viral load in EI studies. Mechanistic viral
load models have been developed for individuals chronically infected with HIV and
hepatitis, and in these cases a normal-errors model is appropriate. In EI studies, however,
it is not because viral load does not vary prior to challenge and during the incubation
period, nor after elimination of the infection. We therefore proposed a NHLM with the
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individual responses at each time point modeled as a Poisson random variable with the
means across time points related through a Tricube mean response function. We
demonstrated application of the model to compare the viral load trajectories in COPD
patients and controls challenged with human rhinovirus, and the time course of influenza
A virus shedding in birds with different, experimentally controlled body conditions. We
discussed estimation of onset and recovery times within the viral load model.
5.2. Limitations and open questions
As we conjectured, the NLHM clearly offer potential gains in estimation and
precision of parameter estimation and power over RM-ANOVA. The extent to which
these gains will be realized in any particular example depends on a number of factors.
Among them are the true effect size, the numbers of subjects per group, the number and
configuration of measurement occasions for each individual, and the amount of
interindividual response variability. Consultation with a biostatistician from the early
stages of study design is highly advisable.
Numerous avenues exist for future work in this area. The asymmetric model
accommodates many more response shapes than the symmetric model, but it is still
limited to single-peaked responses. Some response variables may follow other
trajectories. For example, a proportion of stallions infected with EAV will develop
persistent infections. The viral load in such horses will rise strongly following challenge
and decline after peaking, but will not return to the original zero baseline. Instead it will
stabilize at a new, nonzero baseline level. Antibody responses will exhibit a similar
pattern. In other cases there may be more than one peak, particularly in experiments
involving more than one challenge point. These types of response variables and
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experiments will require different forms for the mean response function. As the response
function increases in complexity, issues of sample size and data collection schedules
become increasingly critical due to the need to estimate a larger number of parameters.
The NLHM is a rich, highly flexible modeling framework with capabilities we
have not explored in this dissertation. For example the effect of covariates such as subject
age, gender and smoking history on the characteristics of the infection response can be
modeled, and the response correlation structure can be explicitly modeled. Successful use
of these features of the NLMH may require larger sample sizes and/or more intensive
observations on individual subjects. Monte Carlo simulation studies can be utilized to
explore feasibility and sample size requirements in the experimental design phase.
Another area we have not explored in great depth is model building and selection.
The NLHM presents an impressive array of modeling options available to the data
analyst. With this flexibility comes the need for tools to compare candidate models.
Systematic and objective methods are needed to decide, for example, whether an
assumption of equal variance across treatment groups is justified. Such questions were
not a primary focus of this work.
5.3. Broader applicability
Peaked data arise in many contexts in which there is interest in experimentally
studying an acute response to an external stimulus. Researchers in a number of fields
have

adopted

the

NLHM

approach

pioneered

in

pharmacokinetics

and

pharmacodynamics for analyzing this time of nonlinear, longitudinal data. Jang et al
(2013) applied piecewise NLHM’s to the analysis of cardiac function (heart rate,
coronary flow, and left ventricle developed pressure) in experiments on myocardial
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ischemia/reperfusion injury (I/R). The goal of such models is to assess the effect of
treatments designed to protect against I/R injury.

G ö ssl et al (2001) developed a

piecewise Bayesian NLHM of the hemodynamic response function (HRF) which arises in
functional magnetic resonance imaging. The HRF reflects acute changes in blood flow
and oxygenation levels in response to neuronal stimulation in the brain. Insulin and
blood glucose levels follow an acute, single-peaked response pattern following food
consumption, and insulin and blood glucose response curves are commonly used in
nutrition and diabetes research (Fernandez-Raudales 2012). Salivary cortisol is a
commonly used as a biomarker for stress, and salivary cortisol profiles are used to
characterize the response to acute stressors (Sanchez 2012). Numerous other examples
can be cited. There remain disciplines within which classical methods such as RMANOVA for modeling longitudinal data are still predominant. The models and
approaches introduced in this dissertation may have applications in a number of domains
outside of EI studies.
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APPENDIX A.
Supplemental material for illustrative applications
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§ 2.4. Febrile response to EAV in horses (symmetric model)

Figure A.1. Observed subject-specific core body temperature profiles for eight mares
experimentally challenged with the Bucyrus strain of EAV

Figure A.2. Observed subject-specific core body temperature profiles for eight stallions
experimentally challenged with the KY-84 strain of EAV
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Figure A.3. Estimated subject-specific febrile response functions

Figure A.4. Composite residual plot
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§ 3.4.1. Lymphocyte response to EAV infection in horses
myModel <- function() {
for (i in 1:n) {
Response[i] ~ dnorm(f[i], pow(s.e,-2))
f[i] <- step(p[Subject[i]]-DPI[i])*(B[Subject[i]]+I[Subject[i]]*exp(pow(DPI[i]-p[Subject[i]],2)/(2*pow(l[Subject[i]],2)))) +
step(DPI[i]-p[Subject[i]])*(B[Subject[i]]+I[Subject[i]]*exp(pow(DPI[i]-p[Subject[i]],2)/(2*pow(r[Subject[i]],2))))
res[i] <- Response[i] - f[i]
}
# Hyperparameters for mean, standard deviation, baseline and intensity
for (j in 1:8) {
B[j] ~ dnorm(m.B,pow(s.B,-2))
I[j] ~ dnorm(m.I,pow(s.I,-2))
p[j] ~ dnorm(m.p,pow(s.p,-2))
l[j] ~ dlnorm(m.log_l,pow(s.log_l,-2))
r[j] ~ dlnorm(m.log_r,pow(s.log_r,-2))
}
# Hyperpriors
m.B ~ dunif(0,5)
m.I ~ dunif(-10,0)
m.p ~ dunif(0,42)
m.log_l ~ dunif(0,5)
m.log_r ~ dunif(0,5)
s.e ~ dunif(0,100)
s.B ~ dunif(0,6)
s.I ~ dunif(0,6)
s.p ~ dunif(0,22)
s.log_l ~ dunif(0,2)
s.log_r ~ dunif(0,2)
# FWHM
HWHM.o <- 2.355*0.5*exp(m.log_l)
HWHM.r <- 2.355*0.5*exp(m.log_r)
FWHM <- HWHM.l + HWHM.r
}

Figure A.5. JAGS model for lymphocyte example
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Table A.1. Posterior summary for lymphocyte example
3 chains, each with 1e+05 iterations (first 25000 discarded)
n.sims = 225000 iterations saved
mu.vect sd.vect
2.5%
25%
50%
75%
97.5%
FWHM
5.462
0.627
4.382
5.054
5.414
5.816
6.814
HWHM.o
4.051
0.528
3.064
3.711
4.036
4.374
5.116
HWHM.r
1.412
0.307
1.182
1.233
1.315
1.471
2.233
m.B
1.523
0.083
1.358
1.475
1.523
1.572
1.688
m.I
-0.834
0.096
-1.027
-0.890
-0.834
-0.778
-0.644
m.log_l
1.227
0.132
0.956
1.148
1.232
1.312
1.469
m.log_r
0.164
0.172
0.004
0.046
0.110
0.222
0.640
m.p
8.265
0.365
7.640
8.004
8.231
8.499
9.046
s.B
0.215
0.081
0.115
0.162
0.198
0.249
0.417
s.I
0.210
0.106
0.052
0.142
0.193
0.259
0.466
s.e
0.141
0.011
0.122
0.133
0.140
0.148
0.164
s.log_l
0.167
0.139
0.008
0.071
0.139
0.227
0.502
s.log_r
0.923
0.548
0.089
0.453
0.849
1.377
1.935
s.p
0.316
0.266
0.010
0.124
0.259
0.439
0.961
deviance -131.779
9.666 -148.543 -138.648 -132.513 -125.708 -110.832

Figure A.6. Observed subject-specific lymphocyte profiles
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Rhat n.eff
1.001 17000
1.001 26000
1.001
9100
1.001 93000
1.001 39000
1.002 18000
1.001 27000
1.001 220000
1.001 44000
1.001 220000
1.001 87000
1.001
5300
1.001 29000
1.001 70000
1.001 64000

Figure A.7. Estimated subject-specific lymphocyte response functions

Figure A.8. Composite residual plot
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§ 3.4.2. Febrile response to EAV infection in horses (asymmetric model)
myModel <- function() {
for (i in 1:n_A) {
y_A[i] ~ dnorm(f_A[i], pow(s.e,-2))
f_A[i] <- ifelse(p_A[Subject_A[i]]>=DPI_A[i],
B_A[Subject_A[i]]+I_A[Subject_A[i]]*exp(-pow(DPI_A[i]p_A[Subject_A[i]],2)/(2*pow(l_A[Subject_A[i]],2))),
B_A[Subject_A[i]]+I_A[Subject_A[i]]*exp(-pow(p_A[Subject_A[i]]DPI_A[i],2)/(2*pow(r_A[Subject_A[i]],2))))
res_A[i] <- y_A[i] - f_A[i]
}
for (i in 1:n_B) {
y_B[i] ~ dnorm(f_B[i], pow(s.e,-2))
f_B[i] <- ifelse(p_B[Subject_B[i]]>=DPI_B[i],
B_B[Subject_B[i]]+I_B[Subject_B[i]]*exp(-pow(DPI_B[i]p_B[Subject_B[i]],2)/(2*pow(l_B[Subject_B[i]],2))),
B_B[Subject_B[i]]+I_B[Subject_B[i]]*exp(-pow(p_B[Subject_B[i]]DPI_B[i],2)/(2*pow(r_B[Subject_B[i]],2))))
res_B[i] <- y_B[i] - f_B[i]
}
# Hyperparameters for mean, standard deviation, baseline and intensity
for (j in 1:8) {
B_A[j] ~ dnorm(m.B_A, pow(s.B_A,-2))
I_A[j] ~ dnorm(m.I_A, pow(s.I_A,-2))
p_A[j] ~ dnorm(m.p_A, pow(s.p_A,-2))
logl_A[j] ~ dnorm(m.logl_A,pow(s.logl_A,-2))
logr_A[j] ~ dnorm(m.logr_A,pow(s.logr_A,-2))
l_A[j] <- exp(logl_A[j])
r_A[j] <- exp(logr_A[j])
}
for (j in 1:8) {
B_B[j] ~ dnorm(m.B_B, pow(s.B_B,-2))
I_B[j] ~ dnorm(m.I_B, pow(s.I_B,-2))
p_B[j] ~ dnorm(m.p_B, pow(s.p_B,-2))
logl_B[j] ~ dnorm(m.logl_B,pow(s.logl_B,-2))
logr_B[j] ~ dnorm(m.logr_B,pow(s.logr_B,-2))
l_B[j] <- exp(logl_B[j])
r_B[j] <- exp(logr_B[j])
}
# Hyperpriors
m.B_A ~ dunif(90,110); m.B_B ~ dunif(90,110)
m.I_A ~ dunif(0,20); m.I_B ~ dunif(0,20)
m.p_A ~ dunif(0,42); m.p_B ~ dunif(0,42)
m.logl_A ~ dunif(0,5); m.logl_B ~ dunif(0,5)
m.logr_A ~ dunif(0,5); m.logr_B ~ dunif(0,5)
s.e ~ dunif(0,100)
s.B_A ~ dunif(0,10); s.B_B ~ dunif(0,10)
s.I_A ~ dunif(0,6); s.I_B ~ dunif(0,6)
s.p_A ~ dunif(0,12); s.p_B ~ dunif(0,12)
s.logl_A ~ dunif(0,4); s.logl_B ~ dunif(0,4)
s.logr_A ~ dunif(0,4); s.logr_B ~ dunif(0,4)
# Differences
m.B_diff <- m.B_B - m.B_A
m.I_diff <- m.I_B - m.I_A
m.p_diff <- m.p_B - m.p_A
HWHM.l_A <- 0.5*2.355*exp(m.logl_A); HWHM.l_B <- 0.5*2.355*exp(m.logl_B)
HWHM.r_A <- 0.5*2.355*exp(m.logr_A); HWHM.r_B <- 0.5*2.355*exp(m.logr_B)
FWHM_A <- HWHM.l_A + HWHM.r_A; FWHM_B <- HWHM.l_B + HWHM.r_B
FWHM_diff <- FWHM_B - FWHM_A
m.logl_diff <- m.logl_B - m.logl_A
m.logr_diff <- m.logr_B - m.logr_A
}

Figure A.9. JAGS model for febrile response example
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Table A.2. Posterior summary for febrile response example
3 chains, each with 1e+05 iterations
n.sims = 225000 iterations saved
mu.vect sd.vect
2.5%
FWHM_A
5.693
0.694
4.813
FWHM_B
5.590
0.419
4.812
FWHM_diff
-0.103
0.807 -1.620
HWHM.l_A
4.260
0.400
3.510
HWHM.l_B
4.260
0.415
3.473
HWHM.r_A
1.433
0.540
1.182
HWHM.r_B
1.330
0.139
1.182
m.B_A
99.372
0.202 98.967
m.B_B
99.261
0.191 98.878
m.B_diff
-0.112
0.277 -0.659
m.I_A
3.463
0.388
2.687
m.I_B
4.669
0.281
4.107
m.I_diff
1.206
0.479
0.253
m.logl_A
1.281
0.094
1.092
m.logl_B
1.281
0.097
1.082
m.logl_diff
0.000
0.135 -0.268
m.logr_A
0.168
0.205
0.004
m.logr_B
0.117
0.096
0.004
m.logr_diff -0.051
0.227 -0.626
m.p_A
7.776
0.260
7.307
m.p_B
7.067
0.207
6.640
m.p_diff
-0.709
0.328 -1.389
s.B_A
0.455
0.209
0.172
s.B_B
0.435
0.197
0.152
s.I_A
0.905
0.404
0.349
s.I_B
0.551
0.334
0.053
s.e
0.679
0.032
0.619
s.logl_A
0.095
0.090
0.003
s.logl_B
0.182
0.100
0.026
s.logr_A
0.781
0.711
0.035
s.logr_B
0.235
0.186
0.011
s.p_A
0.228
0.199
0.010
s.p_B
0.271
0.193
0.015

(first 25000 discarded)
25%
5.322
5.324
-0.474
3.993
3.998
1.231
1.229
99.254
99.147
-0.285
3.232
4.504
0.908
1.221
1.222
-0.087
0.044
0.043
-0.121
7.599
6.941
-0.919
0.317
0.304
0.637
0.328
0.657
0.034
0.117
0.298
0.108
0.087
0.130

50%
5.611
5.574
-0.048
4.248
4.250
1.309
1.294
99.374
99.261
-0.113
3.463
4.669
1.205
1.283
1.284
0.000
0.106
0.095
-0.013
7.758
7.075
-0.697
0.415
0.401
0.830
0.505
0.678
0.073
0.168
0.571
0.198
0.180
0.241
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75%
5.941
5.836
0.353
4.508
4.507
1.458
1.392
99.492
99.375
0.061
3.694
4.834
1.504
1.343
1.342
0.087
0.214
0.167
0.070
7.942
7.200
-0.486
0.546
0.527
1.084
0.713
0.701
0.129
0.230
1.014
0.312
0.312
0.369

97.5%
7.026
6.459
1.155
5.075
5.105
2.433
1.672
99.769
99.643
0.441
4.241
5.223
2.157
1.461
1.467
0.265
0.726
0.351
0.269
8.323
7.461
-0.092
0.968
0.915
1.909
1.337
0.747
0.315
0.422
2.897
0.699
0.735
0.739

Rhat n.eff
1.003
1000
1.001 16000
1.004
2200
1.003
1100
1.001 11000
1.002
4000
1.001 33000
1.001 19000
1.001 160000
1.001 80000
1.001 27000
1.001 110000
1.001 110000
1.003
1100
1.001 11000
1.002
3800
1.001
5600
1.001 13000
1.002
3700
1.004
720
1.001 60000
1.003
1200
1.001 26000
1.001 38000
1.001 16000
1.006
1600
1.001 50000
1.001
6100
1.002
6400
1.003
1200
1.002
3000
1.002
5100
1.003
1700

Figure A.10. Observed subject-specific core body temperature profiles for eight mares
experimentally challenged with the Bucyrus strain of EAV

Figure A.11. Observed subject-specific core body temperature profiles for eight stallions
experimentally challenged with the KY-84 strain of EAV
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Figure A.12. Estimated subject-specific febrile response functions for eight mares
experimentally challenged with the Bucyrus strain of EAV

Figure A.13. Estimated subject-specific febrile response functions for eight stallions
experimentally challenged with the KY-84 strain of EAV
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Figure A.14. Composite residual plot for eight mares experimentally challenged with the
Bucyrus strain of EAV

Figure A.15. Composite residual plot for eight stallions experimentally challenged with
the KY-84 strain of EAV

110

§ 4.3.1. Effect of body condition on viral shedding in migratory waterfowl
myModel <- function() {
for (i in 1:n_A) {
y_A[i] ~ dnorm(f_A[i], pow(s.e,-2))
u_A[i] <- ifelse(DPI_A[i] > p_A[Subject_A[i]], (DPI_A[i] p_A[Subject_A[i]])/r_A[Subject_A[i]], (DPI_A[i] - p_A[Subject_A[i]])/l_A[Subject_A[i]])
Infected_A[i] <- (u_A[i] > -1) * (u_A[i] < 1)
f_A[i] <- Infected_A[i] * I_A[Subject_A[i]] * (1-abs(u_A[i])^3)^3
res_A[i] <- y_A[i] - f_A[i]
}
for (i in 1:n_B) {
y_B[i] ~ dnorm(f_B[i], pow(s.e,-2))
u_B[i] <- ifelse(DPI_B[i] > p_B[Subject_B[i]], (DPI_B[i] p_B[Subject_B[i]])/r_B[Subject_B[i]], (DPI_B[i] - p_B[Subject_B[i]])/l_B[Subject_B[i]])
Infected_B[i] <- (u_B[i] > -1) * (u_B[i] < 1)
f_B[i] <- Infected_B[i] * I_B[Subject_B[i]] * (1-abs(u_B[i])^3)^3
res_B[i] <- y_B[i] - f_B[i]
}
# Hyperparameters for mean, standard deviation, baseline and intensity
for (j in 1:10) {
I_A[j] ~ dnorm(m.I_A, pow(s.I_A,-2))
p_A[j] ~ dnorm(m.p_A, pow(s.p_A,-2))
l_A[j] ~ dnorm(m.l_A,pow(s.l_A,-2))
r_A[j] ~ dnorm(m.r_A,pow(s.r_A,-2))
}
for (j in 1:9) {
I_B[j] ~ dnorm(m.I_B, pow(s.I_B,-2))
p_B[j] ~ dnorm(m.p_B, pow(s.p_B,-2))
l_B[j] ~ dnorm(m.l_B,pow(s.l_B,-2))
r_B[j] ~ dnorm(m.r_B,pow(s.r_B,-2))
}
# Hyperpriors
m.I_A ~ dunif(0,1000); m.I_B ~ dunif(0,1000)
m.p_A ~ dunif(0,10); m.p_B ~ dunif(0,10)
m.l_A ~ dunif(0,m.l_A); m.l_B ~ dunif(0,m.l_B)
m.r_A ~ dunif(0,5); m.r_B ~ dunif(0,5)
s.I_A
s.p_A
s.l_A
s.r_A

~
~
~
~

dunif(0,500); s.I_B
dunif(0,5); s.p_B ~
dunif(0,2); s.l_B ~
dunif(0,2); s.r_B ~

~ dunif(0,500)
dunif(0,5)
dunif(0,5)
dunif(0,5)

# Onset and recovery
onset_A <- m.p_A - m.l_A; onset_B <- m.p_B - m.l_B
recov_A <- m.p_A + m.r_A; recov_B <- m.p_B + m.r_B
dur_A <- recov_A - onset_A; dur_B <- recov_B - onset_B
# Differences
m.I_diff <- m.I_B - m.I_A
m.p_diff <- m.p_B - m.p_A
onset_diff <- onset_B - onset_A
recov_diff <- recov_B - recov_A
dur_diff <- dur_B - dur_A
}

Figure A.16. JAGS model for influenza A viral shedding example
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Table A.3. Posterior summary for influenza A viral shedding example
3 chains, each with 2e+05 iterations (first 50000 discarded)
n.sims = 450000 iterations saved
mu.vect sd.vect
2.5%
25%
50%
75%
dur_A
5.679
0.580
4.422
5.307
5.730
6.100
dur_B
4.900
1.138
2.472
4.170
4.972
5.710
dur_diff
-0.779
1.282
-3.432
-1.615
-0.733
0.109
m.I_A
470.195 57.382 354.831 434.943 470.609 505.799
m.I_B
330.751 67.364 196.823 289.538 330.115 371.374
m.I_diff
-139.445 88.478 -313.574 -196.341 -139.857 -83.562
m.l_A
1.290
0.405
0.383
1.038
1.331
1.579
m.l_B
1.514
0.659
0.214
1.054
1.537
1.977
m.p_A
1.877
0.293
1.310
1.690
1.871
2.056
m.p_B
2.476
0.582
1.357
2.104
2.459
2.828
m.p_diff
0.599
0.651
-0.663
0.176
0.588
1.008
m.r_A
4.389
0.425
3.409
4.126
4.460
4.729
m.r_B
3.387
0.934
1.273
2.804
3.487
4.090
onset_A
0.587
0.414
0.029
0.260
0.513
0.835
onset_B
0.962
0.686
0.042
0.412
0.842
1.388
onset_diff
0.375
0.801
-1.048
-0.174
0.299
0.879
recov_A
6.266
0.509
5.164
5.946
6.311
6.626
recov_B
5.862
1.091
3.520
5.168
5.934
6.632
recov_diff
-0.404
1.205
-2.912
-1.182
-0.353
0.425
s.I_A
165.771 49.995
97.653 131.017 156.162 189.447
s.I_B
188.991 58.930 109.989 147.662 176.860 216.648
s.l_A
1.344
0.320
0.771
1.099
1.332
1.587
s.l_B
2.735
0.731
1.609
2.193
2.622
3.170
s.p_A
0.928
0.275
0.553
0.738
0.876
1.057
s.p_B
1.797
0.562
1.036
1.402
1.685
2.064
s.r_A
1.899
0.088
1.673
1.854
1.923
1.967
s.r_B
3.134
0.773
1.847
2.543
3.053
3.667
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97.5%
6.664
6.911
1.603
583.711
467.642
38.085
1.978
2.757
2.479
3.687
1.927
4.971
4.858
1.561
2.535
2.097
7.148
7.795
1.824
291.298
340.856
1.941
4.465
1.607
3.232
1.997
4.752

Rhat
1.003
1.043
1.031
1.001
1.001
1.001
1.009
1.001
1.002
1.001
1.001
1.001
1.078
1.003
1.001
1.002
1.001
1.044
1.029
1.001
1.001
1.007
1.001
1.001
1.001
1.001
1.108

n.eff
890
74
75
110000
11000
11000
420
15000
3400
8700
170000
34000
52
950
250000
2600
30000
66
82
51000
450000
310
22000
7400
97000
320000
23

Figure A.17. Observed subject-specific viral shedding profiles for ten wild-caught,
normal treatment mallards experimentally challenged with influenza A

Figure A.18. Observed subject-specific viral shedding profiles for nine wild-caught, lean
treatment mallards experimentally challenged with influenza A
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Figure A.19. Estimated subject-specific viral shedding responses for nine captive-bred,
normal treatment mallards experimentally challenged with influenza A

Figure A.20. Estimated subject-specific viral shedding responses for nine wild-caught,
lean treatment mallards experimentally challenged with influenza A
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Figure A.21. Composite residual plot for nine captive-bred, normal treatment mallards
experimentally challenged with influenza A (jittered to show overlapping values more
clearly)

Figure A.22. Composite residual plot for nine wild-caught, lean treatment mallards
experimentally challenged with influenza A (jittered to show overlapping values more
clearly)
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§ 4.3.2. Effects of rhinovirus infection in chronic obstructive pulmonary disease
myModel <- function() {
for (i in 1:n_A) {
y_A[i] ~ dpois(f_A[i])
u_A[i] <- ifelse(DPI_A[i] > p_A[Subject_A[i]], (DPI_A[i] p_A[Subject_A[i]])/r_A[Subject_A[i]], (DPI_A[i] - p_A[Subject_A[i]])/l_A[Subject_A[i]])
Infected_A[i] <- (u_A[i] > -1) * (u_A[i] < 1)
f_A[i] <- Infected_A[i] * I_A[Subject_A[i]] * (1-abs(u_A[i])^3)^3
res_A[i] <- y_A[i] - f_A[i]
}
for (i in 1:n_B) {
y_B[i] ~ dpois(f_B[i])
u_B[i] <- ifelse(DPI_B[i] > p_B[Subject_B[i]], (DPI_B[i] p_B[Subject_B[i]])/r_B[Subject_B[i]], (DPI_B[i] - p_B[Subject_B[i]])/l_B[Subject_B[i]])
Infected_B[i] <- (u_B[i] > -1) * (u_B[i] < 1)
f_B[i] <- Infected_B[i] * I_B[Subject_B[i]] * (1-abs(u_B[i])^3)^3
res_B[i] <- y_B[i] - f_B[i]
}
# Hyperparameters for mean, standard deviation, baseline and intensity
for (j in 1:12) {
I_A[j] ~ dnorm(m.I_A, s.I_A^(-2))
p_A[j] ~ dnorm(m.p_A, s.p_A^(-2))
l_A[j] ~ dnorm(m.l_A, s.l_A^(-2))
r_A[j] ~ dnorm(m.r_A, s.r_A^(-2))
}
for (j in 1:11) {
I_B[j] ~ dnorm(m.I_B, s.I_B^(-2))
p_B[j] ~ dnorm(m.p_B, s.p_B^(-2))
l_B[j] ~ dnorm(m.l_B, s.l_B^(-2))
r_B[j] ~ dnorm(m.r_B, s.r_B^(-2))
}
# Hyperpriors
m.I_A ~ dunif(0,1500); m.I_B
m.p_A ~ dunif(0,42); m.p_B ~
m.l_A ~ dunif(0,50); m.l_B ~
m.r_A ~ dunif(0,50); m.r_B ~
s.I_A
s.p_A
s.l_A
s.r_A

~
~
~
~

~ dunif(0,1500)
dunif(0,42)
dunif(0,50)
dunif(0,50)

dunif(0,500); s.I_B ~ dunif(0,500)
dunif(0,12); s.p_B ~ dunif(0,12)
dunif(0,m.l_A); s.l_B ~ dunif(0,m.l_B)
dunif(0,5); s.r_B ~ dunif(0,5)

# Onset and recovery
onset_A <- m.p_A - m.l_A; onset_B <- m.p_B - m.l_B
recov_A <- m.p_A + m.r_A; recov_B <- m.p_B + m.r_B
dur_A <- recov_A - onset_A; dur_B <- recov_B - onset_B
# Differences
m.I_diff <- m.I_B - m.I_A
m.p_diff <- m.p_B - m.p_A
onset_diff <- onset_B - onset_A
recov_diff <- recov_B - recov_A
dur_diff <- dur_B - dur_A
}

Figure A.23. JAGS model for rhinovirus-COPD example
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Table A.4. Posterior summary rhinovirus for COPD example
dur_A
dur_B
dur_diff
m.I_A
m.I_B
m.I_diff
m.l_A
m.l_B
m.p_A
m.p_B
m.p_diff
m.r_A
m.r_B
onset_A
onset_B
onset_diff
recov_A
recov_B
recov_diff
s.I_A
s.I_B
s.l_A
s.l_B
s.p_A
s.p_B
s.r_A
s.r_B

mu.vect sd.vect
2.5%
18.132
1.489
15.209
17.079
1.636
13.902
-1.052
2.212
-5.369
550.169 47.313 456.112
610.179 83.490 442.470
60.010 95.932 -130.913
0.748
0.408
0.059
1.290
0.622
0.148
3.293
0.816
1.588
2.773
1.062
0.832
-0.520
1.339
-3.026
17.383
1.437
14.564
15.789
1.527
12.808
2.544
0.894
0.703
1.483
1.045
0.061
-1.062
1.374
-3.476
20.676
1.647
17.425
18.562
1.827
15.085
-2.114
2.459
-6.870
148.230 40.478
91.780
247.802 67.127 150.960
1.205
0.431
0.479
2.237
0.609
1.357
2.655
0.683
1.695
3.975
1.599
1.917
4.951
0.048
4.823
4.848
0.140
4.480

25%
17.127
15.972
-2.546
520.565
558.498
-1.072
0.425
0.848
2.787
2.052
-1.425
16.413
14.758
1.965
0.651
-2.027
19.574
17.320
-3.780
119.987
198.981
0.917
1.802
2.177
2.834
4.931
4.784
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50%
18.133
17.069
-1.058
550.149
610.429
60.162
0.735
1.277
3.315
2.726
-0.564
17.385
15.784
2.560
1.323
-1.159
20.679
18.526
-2.137
140.924
235.444
1.173
2.128
2.533
3.613
4.966
4.889

75%
19.134
18.179
0.439
579.700
662.020
121.222
1.054
1.704
3.818
3.425
0.331
18.351
16.817
3.135
2.122
-0.192
21.783
19.756
-0.472
167.901
283.787
1.448
2.554
2.993
4.726
4.986
4.953

97.5%
21.059
20.308
3.295
644.467
777.665
251.366
1.527
2.562
4.870
5.020
2.243
20.206
18.797
4.284
3.869
1.872
23.900
22.262
2.767
247.524
416.018
2.170
3.749
4.326
8.142
4.999
4.996

Rhat
1.019
1.001
1.010
1.001
1.001
1.001
1.280
1.001
1.004
1.001
1.001
1.001
1.001
1.035
1.001
1.021
1.001
1.001
1.001
1.001
1.001
1.682
1.001
1.001
1.001
1.001
1.001

n.eff
110
52000
220
220000
98000
110000
12
64000
1700
220000
7800
35000
54000
68
450000
100
30000
89000
39000
200000
24000
6
67000
9600
9500
190000
450000

Figure A.24. Observed nasal viral load profiles for twelve healthy controls
experimentally challenged with RV-16

Figure A.25. Observed nasal viral load profiles for eleven subjects with COPD
experimentally challenged with RV-16
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Figure A.26. Estimated subject-specific viral shedding responses for twelve healthy
controls experimentally challenged with RV-16

Figure A.27. Estimated subject-specific viral shedding responses for eleven subjects with
COPD experimentally challenged with RV-16
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Figure A.28. Composite residual plot for twelve healthy controls experimentally
challenged with RV-16 (jittered to show overlapping values more clearly)

Figure A.29. Composite residual plot for eleven subjects with COPD experimentally
challenged with RV-16 (jittered to show overlapping values more clearly)
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